,PageNo,Text
0,page_1,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 1 of 92', 'CR845-CLIN3102', 'CARA', 'HERAPEUTICS', 'A MULTICENTER, DOUBLE-BLIND, RANDOMIZED,', 'PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND', 'EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS', 'WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52-WEEK', 'OPEN-LABEL EXTENSION', 'Protocol number:', 'CR845-CLIN3102', 'Phase:', '3', 'IND number:', '123140', 'Protocol version:', 'Version 1.0', 'Date:', 'December 21,2017', 'Sponsor:', 'Cara Therapeutics, Inc.', '4 Stamford Plaza', 'Stamford, CT 06902', '(203) 406-3700', 'Information contained in this document is proprietary and confidential information of Cara Therapeutics,', 'Inc. Any distribution, copying, or disclosure is strictly prohibited unless such disclosure is required by', 'federal regulations or state law. Persons receiving the information in this document are hereby given notice', 'that the information is confidential and may not be further copied, distributed, disseminated or otherwise', 'disclosed to any other person without the express written authorization of Cara Therapeutics, Inc.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 3 of 95']"
1,page_2,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 2 of 92', 'CR845-CLIN3102', 'SPONSOR APPROVAL / SIGNATURE PAGE', 'Date:', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 4 of 95']"
2,page_3,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 3 of 92', 'CR845-CLIN3102', 'INVESTIGATOR APPROVAL STATEMENT', 'I have read and understand the protocol (CR845-CLIN3102) and I agree that this', 'document contains all ethical, legal, and scientific information necessary to conduct this', 'study. I will oversee the conduct of the study as described in the protocol and any', 'amendment(s) made to the protocol.', 'I agree to conduct the study as detailed herein and in compliance with the current', 'International Council for Harmonisation Harmonised Tripartite Guideline for Good', 'Clinical Practice E6 (R1) and United States Code Title 21 (Food and Drug', 'Administration), and applicable regulatory requirements.', 'Principal Investigator', 'Printed Name:', 'Signature:', 'Date:', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 5 of 95']"
3,page_4,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 4 of 92', 'CR845-CLIN3102', '1.0', 'Protocol Synopsis', 'STUDY TITLE', 'A Multicenter, Double-blind, Randomized, Placebo-controlled Study to', 'Evaluate the Safety and Efficacy of Intravenous CR845 in', 'Hemodialysis Patients with Moderate-to-Severe Pruritus, with a', '52-Week Open-label Extension', 'PROTOCOL', 'CR845-CLIN3102', 'NUMBER', 'PHASE OF', '3', 'DEVELOPMENT', 'INVESTIGATIONAL', 'CR845 Solution', 'PRODUCT', 'NAME OF ACTIVE', 'CR845', 'INGREDIENT', 'ROUTE OF', 'Intravenous (IV)', 'ADMINISTRATION', 'STUDY CENTERS', 'Up to 80 sites in the United States', 'OBJECTIVES', 'Primary Objective', 'To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg', 'compared to placebo in reducing the intensity of itch in', 'hemodialysis patients with moderate-to-severe pruritus.', 'Secondary Objectives', 'To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg', 'compared to placebo in improving itch-related quality-of-life', 'measures in hemodialysis patients with moderate-to-severe', 'pruritus.', 'To evaluate the safety of IV CR845 at a dose of 0.5 mcg/kg in', 'hemodialysis patients with moderate-to-severe pruritus.', 'NUMBER OF', 'The planned sample size is 350 (175 per treatment group) male and', 'PATIENTS', 'female hemodialysis patients with moderate-to-severe pruritus. The', 'sample size may be increased to 500 patients (250 per treatment group)', 'based on the results of a planned interim assessment conducted when', 'approximately 50% of the planned 350 patients have been randomized', 'and have either completed the 12-week Treatment Period or have', 'discontinued study drug early.', 'STUDY', 'Inclusion Criteria:', 'POPULATION', 'To be eligible for inclusion into the Double-blind Phase of the study, a', 'patient must meet the following criteria:', '1.', 'Willing and able to provide written informed consent prior to', 'participating in this study;', '2. Able to communicate clearly with the Investigator and staff,', 'able to understand the study procedures, and able and willing', 'to comply with the study requirements;', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 6 of 95']"
4,page_5,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 5 of 92', 'CR845-CLIN3102', '3. Male or female 18 years of age or older;', '4.', 'Has end-stage renal disease (ESRD) and has been on', 'hemodialysis 3 times per week for at least 3 months prior to', 'the start of screening;', 'Note 1: Patients who require an occasional additional dialysis', 'treatment to manage fluid overload may be enrolled as long as', 'it is anticipated that no more than 1 such treatment will be', 'required in any given week.', 'Note 2: Patients receiving in-home hemodialysis may', 'participate as long as they have switched to in-center', 'hemodialysis at least 2 weeks prior to screening and plan to', 'remain on in-center hemodialysis for the duration of the', 'study.', '5. If female, is not pregnant or nursing during any period of the', 'study;', '6. If female:', 'a.', 'Is surgically sterile; or', 'b. Has been amenorrhoeic for at least 1 year and is over the', 'age of 55 years; or', 'c.', 'Has a negative serum pregnancy test at screening and', 'agrees to use acceptable contraceptive measures', '(eg, hormonal contraceptives, barrier with spermicide,', 'intrauterine device, vasectomized partner, or abstinence)', 'from the time of informed consent until 7 days after the', 'last dose of study drug;', '7.', 'If male, agrees not to donate sperm after the first dose of study', 'drug until 7 days after the last dose of study drug, and agrees to', 'use a condom with spermicide or abstain from heterosexual', 'intercourse during the study until 7 days after the last dose of', 'study drug. (Note: No restrictions are required for a', 'vasectomized male provided his vasectomy was performed', '>4 months prior to screening);', '8. Has a prescription dry body weight between 40.0 and 135.0 kg,', 'inclusive;', '9.', 'Has at least 2 single-pool Kt/V measurements 1.2, or at least', '2 urea reduction ratio measurements 65%, or 1 single-pool', 'Kt/V measurement >1.2 and 1 urea reduction ratio', 'measurement >65% on different dialysis days during the', '3 months period prior to screening;', '10. Prior to randomization:', 'a.', 'Has completed at least 4 Worst Itching Intensity NRS', 'worksheets from the start of the 7-day Run-in Period up to', 'and including the pre-randomization assessment on Day 1;', 'b. Has a mean baseline Worst Itching Intensity NRS score', '>4, defined as the average of all non-missing scores', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 7 of 95']"
5,page_6,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 6 of 92', 'CR845-CLIN3102', 'reported from the start of the 7-day Run-in Period up to', 'and including the pre-randomization assessment on Day 1.', 'To be eligible for inclusion into the Open-label Extension Phase of', 'the study, each patient will have to fulfill the additional following', 'criteria at the time of entry into the Open-label Extension Phase:', '11. Has received at least 30 doses of the planned 36 doses of study', 'drug during the Double-blind Phase of this study;', '12. Has a prescription dry body weight >40 kg;', '13. Continues to meet inclusion criteria 1 through 7.', 'Exclusion Criteria:', 'A patient will be excluded from the Double-blind Phase of the study if', 'any of the following criteria are met:', '1. Known noncompliance with dialysis treatment that in the', 'opinion of the investigator would impede completion or', 'validity of the study;', '2. Scheduled to receive a kidney transplant during the study;', '3.', 'Known history of allergic reaction to opiates, such as hives', '(Note: side effects related to the use of opioids, such as', 'constipation or nausea, would not exclude patients from the', 'study).', '4. Has a concomitant disease or a history of any medical', 'condition that, in the opinion of the Investigator, could pose', 'undue risk to the patient, impede completion of the study', 'procedures, or would compromise the validity of the study', 'measurements, including, but not limited to:', 'a.', 'Known or suspected history of alcohol, narcotic, or other', 'drug abuse, or substance dependence within 12 months', 'prior to screening;', 'b.', 'Significant systolic or diastolic heart failure (eg, New', 'York Heart Association Class IV congestive heart failure', '[Appendix 1, Section 14.1]);', 'c.', 'Severe mental illness or cognitive impairment (eg,', 'dementia);', 'd. Any other relevant acute or chronic medical or', 'neuropsychiatric condition within 3 months prior to', 'screening (eg, diagnosis of encephalopathy, coma,', 'delirium);', '5.', 'New or change of treatment received for itch including', 'antihistamines and corticosteroids (oral, IV, or topical) within', '14 days prior to screening;', '6.', 'New or change of prescription for opioids, gabapentin, or', 'pregabalin within 14 days prior to screening;', '7.', 'Received another investigational drug within 30 days prior to', 'the start of screening or is planning to participate in another', 'clinical study while enrolled in this study;', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 8 of 95']"
6,page_7,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 7 of 92', 'CR845-CLIN3102', '8. In the opinion of the Investigator, has pruritus attributed to a', 'cause other than ESRD or its complications (eg, patients with', 'concomitant pruritic dermatological disease or cholestatic liver', 'disease) (Note: Patients whose pruritus is attributed to ESRD', 'complications, such as hyperparathyroidism,', 'hyperphosphatemia, anemia, or the dialysis procedure or', 'prescription may be enrolled);', '9. Has localized itch restricted to the palms of the hands;', '10. Has pruritus only during the dialysis session (by patient', 'report);', '11. Is receiving ongoing ultraviolet B treatment and anticipates', 'receiving such treatment during the study;', '12. Participated in a previous clinical study with CR845.', 'A patient will be excluded from the Open-label Extension Phase of', 'the study if any of the additional following criteria are met at the', 'time of entry into the Open-label Extension Phase:', '13. Completed the Double-blind Phase of this study but exhibited', 'adverse events during the course of the Treatment Period that', 'may preclude continued exposure to the study drug;', '14. Was noncompliant with protocol procedures during the', 'Double-blind Phase of this study which is indicative of an', 'inability to follow protocol procedures;', '15. Has developed a concomitant disease or any medical condition', 'that, in the opinion of the Investigator, could pose undue risk', 'to', 'the patient, impede completion of the study procedures, or', 'would compromise the validity of the study measurements.', 'STUDY DESIGN', 'This is a multicenter, randomized, double-blind, placebo-controlled', 'study to evaluate the safety and efficacy of IV CR845 at a dose of', '0.5 mcg/kg administered after each dialysis session. The study', 'includes a Double-blind Phase and an Open-label Extension Phase.', 'Double-blind Phase', 'The Double-blind Phase of the study will consist of a Screening Visit, a', '7-day Run-in Period, a 12-week Double-blind Treatment Period, and a', '2-week Discontinuation Period. Informed consent will be obtained', 'prior to performing any study-specific procedures. The Screening Visit', 'will occur within 7 to 28 days prior to randomization to assess', 'eligibility. The site has the option to conduct the Screening Visit', 'within the Run-in Period at the discretion of the Investigator.', 'Eligible patients will complete a 7-day Run-in Period during the week', 'prior to randomization to confirm eligibility, starting on the first', 'dialysis session of that week (ie, Monday for patients on a', 'Monday-Wednesday-Friday dialysis schedule or Tuesday for patients', 'on a Tuesday-Thursday-Saturday dialysis schedule). The purpose of', 'the Run-in Period is to confirm that each patient has', 'moderate-to-severe pruritus (ie, weekly average worst itch score >4), as', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 9 of 95']"
7,page_8,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 8 of 92', 'CR845-CLIN3102', 'measured by the patient-daily reported 24-hour Worst Itching Intensity', 'NRS, and to establish a baseline itch intensity. Patients must not be', 'informed that they need to report a weekly average worst itch score', '>4 to be enrolled in the study. During the first visit of the Run-in', 'Period, patients will be trained on completion of the 24-hour Worst', 'Itching Intensity numerical rating scale (NRS) and will start the', 'reporting of their Worst Itching Intensity NRS daily score. For', 'consistency, patients will be requested to complete the NRS', 'worksheets (either at home or in the dialysis unit, as required) each day', 'at a similar time of day around the normal start time of their dialysis.', 'Patients will be trained on other itch-related patient-reported outcome', '(PRO) worksheets during the Run-in Period or on Day 1 of the', 'Double-blind Treatment Period.', 'If patients continue to meet all inclusion and no exclusion criteria at the', 'end of the 7-day Run-in Period, they will be randomized into the', 'Double-blind Treatment Period in a 1:1 ratio to receive either IV', 'CR845 0.5 mcg/kg or placebo. Patients will be stratified according to', 'their use or non-use of concomitant medications to treat their itch', 'during the week prior to randomization (Run-in Period) as well as the', 'presence or absence of specific medical conditions. These specific', 'medical conditions include:', 'History of fall or fracture (related to fall)', 'Confusional state or mental status change or altered mental', 'status or disorientation', 'Gait disturbance or movement disorder', 'Day 1 of the Double-blind Treatment Period will be defined as the day', 'of administration of the first dose of study drug and will occur on the', 'first dialysis session of the first treatment week (ie, Monday for', 'patients on a Monday-Wednesday-Friday dialysis schedule, or Tuesday', 'for patients on a Tuesday-Thursday-Saturday dialysis schedule).', 'Patients will be administered CR845 or matched placebo as an IV', 'bolus after the end of each dialysis session during the 12-week', 'Double-blind Treatment Period. Each patient is to receive CR845 or', 'placebo 3 times weekly for a total of up to 36 doses.', 'During the Double-blind Treatment Period, patients will continue to', 'report their daily Worst Itching Intensity NRS score over the previous', '24 hours. In addition, during selected study visits (Day 1 and first day', 'of Weeks 5, 9, 11, and 13; ie Days 29, 57, 71, and 85), they will', 'complete other PRO measures (Skindex-10 Scale, 5-D Itch Scale, and', 'Patient Global Impression of Change). Patients will be instructed to', 'record patient-reported outcome measurements at a similar time of day,', 'whether in the dialysis unit (on dialysis days) or at home', '(on non-dialysis days).', 'Blood samples for clinical laboratory tests will be collected at the', 'Screening Visit, Days 1 and 85. Blood samples for biomarkers will be', 'collected at Days 1 and 85. Electrocardiograms (ECGs) will be', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 10 of 95']"
8,page_9,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 9 of 92', 'CR845-CLIN3102', 'monitored at the Screening Visit and Day 85. Vital signs will be', 'monitored periodically, and adverse events and concomitant', 'medications will be continuously recorded starting at the Screening', 'Visit until the end of the Discontinuation Period or Early Termination', 'Visit. Use of antipruritic medications, iron, and', 'erythropoiesis-stimulating agents (ESAs) and missed dialysis will be', 'recorded throughout the Double-blind Phase.', 'The Double-blind Treatment Period will be followed by a 2-week', 'Discontinuation Period, during which no study drug will be', 'administered. Patients will be monitored and evaluated for potential', 'physical dependence by completing a Short Opiate Withdrawal Scale', '(ShOWS) daily on dialysis days and on non-dialysis days. Objective', 'Opiate Withdrawal Scale (OOWS) score, adverse events, concomitant', 'medication, body temperature, and vital signs measurements will also', 'be collected at each dialysis visit. During this period, patients will', 'continue to report their NRS scores but only on the dialysis visit.', 'A Structured Safety Evaluation will be performed once during the', 'Run-in Period and weekly (preferably on Wednesday/Thursday) during', 'the Double-blind Treatment Period and Discontinuation Period. The', 'Structured Safety Evaluation is performed by study staff using a list of', 'specific signs/symptoms (eg, mental status change, falls, gait', 'disturbance).', 'Open-label Extension Phase', 'Patients who received at least 30 doses of study drug (either active or', 'placebo) during the 12-week Double-blind Treatment Period and', 'continue to meet other eligibility criteria will have the option to receive', 'open-label CR845 for an additional 52 weeks. The Open-label', 'Extension Phase will be comprised of the Open-label Treatment Period', 'and the Follow-up Period.', 'Each patient will receive CR845 at a dose of 0.5 mcg/kg after each', 'dialysis session, 3 times per week for up to 52 weeks, regardless of', 'whether they had been previously administered placebo or CR845.', 'Prescription dry weight will be recorded every 12 weeks; if there is a', '>10% change from the previous recorded dry weight, then the CR845', 'dose will be adjusted.', 'The first visit and first dosing for the Open-label Extension Phase of', 'the study will occur during the week (+1-week window) following the', 'Discontinuation Period.', 'Patients will complete the 5-D Itch Scale during Weeks 4, 8, 12, 24,', '36, and 52 (preferably at the end of the specified weeks).', 'Clinical laboratory tests, vital signs, adverse events, and concomitant', 'medications will be monitored throughout the Open-label Treatment', 'Period. Blood samples for inflammatory biomarkers will be collected', 'periodically until the Open-label End-of-Treatment or Early', 'Termination Visit. ECGs will be monitored at the Open-label', 'End-of-Treatment or Early Termination Visit.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 11 of 95']"
9,page_10,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 10 of 92', 'CR845-CLIN3102', 'The number and reason(s) for missed dialysis as well as the use of', 'antipruritic medications, ESAs and iron will be recorded throughout', 'the Open-label Treatment Period.', 'The last dose of open-label study drug will be administered at the last', 'dialysis visit on Week 52, or Early Termination. A final safety', 'Follow-up Visit will be conducted 7-10 days after the', 'End-of-Treatment/Early Termination Visit.', 'STUDY DRUG', 'Study drug will be supplied in glass vials containing an extractable', 'volume of at least 1.3 mL of CR845 at a concentration of 0.05 mg/mL', 'in 0.04M isotonic acetate buffer, pH 4.5.', 'REFERENCE', 'Matching placebo (0.04M isotonic acetate buffer, pH 4.5) will be', 'PRODUCT', 'provided in glass vials containing an extractable volume of at least', '1.3 mL.', 'TREATMENT', 'Patients will be administered CR845 0.5 mcg/kg or placebo as a single', 'REGIMENS', 'IV bolus 3 times a week after each dialysis session for 12 weeks during', 'the Double-blind Treatment Period.', 'No study drug will be administered during the Discontinuation Period.', 'During the Open-label Treatment Period, patients will be administered', 'CR845 0.5 mcg/kg as a single IV bolus 3 times a week after each', 'dialysis session for up to 52 weeks.', 'STUDY DURATION', 'Double-blind Phase:', 'Screening Period: up to 4 weeks (may occur during Run-in Period at', 'the discretion of Investigator) inclusive of the 7-day Run-in Period', 'Double-blind Treatment Period: 12 weeks', 'Discontinuation Period: 2 weeks', 'Open-label Extension Phase:', 'Open-label Treatment Period: up to 52 weeks', 'Follow-up Period: 2 weeks', 'Total study duration for a single patient: up to approximately 72 weeks', 'STUDY', 'Efficacy Endpoints', 'ENDPOINTS', 'Primary Efficacy Endpoint', 'Proportion of patients achieving at least a 3-point improvement', 'from baseline with respect to the weekly mean of the daily 24-', 'hour Worst Itching Intensity NRS score at Week 12 of the', 'Double-blind Treatment Period', 'Secondary Efficacy Enppoints', 'Change from baseline in itch-related quality of life at the end', 'of Week 12 of the Double-blind Treatment Period, as assessed', 'by the 5-D Itch Scale total score', 'Change from baseline in itch-related quality of life at the end', 'of Week 12 of the Double-blind Treatment Period, as assessed', 'by the Skindex-10 Scale total score', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 12 of 95']"
10,page_11,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 11 of 92', 'CR845-CLIN3102', 'Proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 12 of the Double-blind', 'Treatment Period.', 'Additional efficacy endpoints are described in Section 8.7.4.', 'Safety Endpoints', 'The safety endpoints used to evaluate the overall safety and tolerability', 'of CR845 will be adverse events, ECG, vital signs, and clinical safety', 'laboratory evaluations.', 'INTERIM', 'Safety data will be reviewed on an ongoing basis by the Sponsor and a', 'ASSESSMENT', 'Data Safety Monitoring Board (DSMB). The operation of the DSMB', '(Double-blind Phase)', ""will be governed by a charter that will describe the group's meeting"", 'frequency, procedures, and requirements for reporting its observations', 'to the Sponsor.', 'A single interim assessment for sample size re-estimation is planned', 'after approximately 50% of the first 350 randomized patients either', 'complete the 12-week Double-blind Treatment Period or discontinue', 'study drug prematurely. The interim assessment will be conducted by', 'an Independent Data Monitoring Committee (IDMC). Members of the', 'IDMC will not participate in the DSMB and will not be members of the', 'study team. During the interim assessment, the study team will remain', 'blinded to the data; however, the IDMC will receive unblinded', 'summary results to implement the decision rule for sample size re-', 'estimation. The IDMC will only communicate the decision to either', 'keep the original sample size or to increase it; no other results will be', 'provided to blinded staff. The DSMB will be made aware of the', 'decision, but not given the results that were the basis of the decision.', 'STATISTICAL', 'Analysis Populations', 'ANALYSIS', 'The Enrolled Population is defined as the group of patients who sign', 'informed consent.', 'The ITT Population is defined as the group of patients who are', 'randomized to a treatment group. The Double-blind Safety Population', 'is defined as the group of randomized patients who received at least', '1', 'dose of study drug during the Double-blind Treatment Period.', 'Following the intent-to-treat principle, patients in the ITT will be', 'analyzed according to their randomized treatment, regardless of the', 'actual treatment received. Patients in the Double-blind Safety Analysis', 'Population will be analyzed according to the actual treatment received.', 'The Double-blind Safety Population will be used to analyze all safety', 'endpoints collected during the Double-blind Phase, while the ITT', 'Population will be used to analyze all efficacy endpoints collected', 'during the Double-blind Phase.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 13 of 95']"
11,page_12,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 12 of 92', 'CR845-CLIN3102', 'The Per-Protocol Population is defined as the subset of patients in the', 'ITT who do not have any major protocol deviations that could affect', 'the efficacy analyses of the double-blind data.', 'Inclusion in the Per-Protocol Population will be determined prior to', 'unblinding the data and will be detailed in the statistical analysis plan.', 'The Open-label Safety Population is defined as the group of patients', 'who receive at least 1 dose of study drug in the Open-label Phase. The', 'Open-label Safety Population will be used to analyze all safety', 'endpoints collected during the Open-label Phase, and during exposure', 'to CR845 combining data from both the Double-blind and the', 'Open-label Phases.', 'Safety Analyses', 'Safety data will be summarized descriptively. No inferential statistics', 'are planned. Analyses of safety data will include summaries of', 'treatment-emergent adverse events including Adverse Events of', 'Special Interest (AESI), serious adverse events, and adverse events', 'resulting in study drug discontinuation. Vital signs, chemistry and', 'hematology data, ECG data will be presented by visit as applicable, in', 'addition to change from baseline.', 'Efficacy Analyses (Double-blind Treatment Period)', 'All efficacy analyses will be conducted on the ITT Population. An', 'analysis of the primary and secondary efficacy variables for the Per-', 'Protocol Population will also be performed.', 'Primary Efficacy Enppoint', 'The primary efficacy endpoint is defined as the proportion of patients', 'achieving at least a 3-point improvement from baseline with respect to', 'the weekly mean of the daily 24-hour Worst Itching Intensity NRS', 'score at Week 12 (Days 79-85) of the Double-blind Treatment Period.', 'The weekly mean of the 24-hour Worst Itching Intensity NRS score', 'will be defined as the sum of the daily Worst Itching Intensity NRS', 'score reported during a specific week during the Double-blind', 'Treatment Period (eg, Days 2 to 8, Days 9 to 15, Days 16 to 22, etc,.', 'Days 79 to 85) divided by the number of days with non-missing scores', 'for that week. If the daily worst itching score is missing for >3 days', 'during a specific week, the corresponding weekly mean worst itching', 'score will be set to missing. The baseline score will be defined as the', 'average of the daily 24-hour Worst Itching Intensity NRS scores', 'collected over the Run-in Period, including pre-randomization', 'assessments collected on Day 1.', 'In the primary efficacy analysis, missing NRS data will be imputed', 'using a multiple imputation (MI) approach, assuming that patients who', 'discontinue double-blind treatment early would have similar Worst', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 14 of 95']"
12,page_13,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 13 of 92', 'CR845-CLIN3102', 'Itching Intensity NRS scores as other patients in their respective', 'treatment arm that have complete data:', 'Intermittent missing NRS scores will first be imputed using the', 'Markov Chain Monte Carlo (MCMC) method implemented with', 'the SAS MI procedure, which is appropriate for non-monotonic', 'missing data.', 'NRS scores missing after patients discontinue study drug early will', 'then be multiply imputed with the SAS MI procedure using a', 'method appropriate for monotone missingness (eg, regression', 'statement).', 'The proportion of patients who have an improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS score 3 points will be calculated for', 'each imputed dataset. Differences between CR845 0.5 mcg/kg and', 'placebo with respect to the primary endpoint will be compared', 'using a logistic regression model containing terms for treatment', 'group, baseline NRS score, use of prior anti-itch medication, and', 'presence of specific medical conditions', 'Results of the logistic regression on the multiply imputed data sets', 'will be summarized by the SAS MIANALYZE procedure.', 'Sensitivity analyses of the primary efficacy endpoint will be conducted', 'to evaluate the robustness of study results under different assumptions', 'and imputation algorithms (Section 8.7.1).', 'Secondary Efficacy Enpoints', 'The Skindex-10 Scale total score and the 5-D Itch Scale total score will', 'be analyzed using a mixed effects model with repeated measures', '(MMRM) that will contain treatment, week, and treatment-by-week', 'interaction as fixed effects; baseline score, prior anti-itch medication', 'usage and presence of specific medical conditions as covariates; and', 'patient as a random effect. Repeated measures will include values', 'collected at the end of Weeks 4, 8, 10, and 12 (end of treatment). The', 'mean treatment difference between CR845 0.5 mcg/kg and placebo', 'will be estimated as the simple contrast in the treatment effect at', 'Double-blind Treatment Period Week 12.', 'It is important to note that, in HD patients, the study drug administered', 'during the last dialysis of a particular week is not cleared until the first', 'dialysis of the next week. Therefore, measurements that would reflect', 'treatment effect at the end of a specific week (eg. Week 4) will actually', 'be collected during the first day of the next week (eg. Week 5).', 'The proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour Worst', 'Itching Intensity NRS at Week 12 of the Double-blind Treatment', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 15 of 95']"
13,page_14,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 14 of 92', 'CR845-CLIN3102', 'Period will be analyzed follow a similar mehtodology to the one', 'employed in the primary analysis of the primary endpoint.', 'Hypothesis Testing Strategy', 'Testing of the primary efficacy endpoint will be 2-sided and conducted', 'at the 5% error level. The study will be considered positive if the null', 'hypothesis of no treatment difference in the primary efficacy analysis', 'of the primary endpoint (proportion of patients with a 3-point', 'improvement from baseline at Week 12 of the Double-blind Treatment', 'Period with respect to the Worst Itching Intensity NRS) is rejected in', 'favor of the alternative that patients randomized to CR845 experience', 'significantly less itching compared to patients randomized to placebo.', 'To protect the Type 1 error, a gate-keeping strategy will be', 'implemented. Although the p-values corresponding to the hypothesis', 'testing of the secondary variables will be reported, they will only be', 'considered inferential if the primary analysis is statistically significant.', 'Testing of the secondary efficacy endpoints will be performed', 'sequentially at a 2-sided 5% error level. The difference between', 'CR845 0.5 mcg/kg and placebo with respect to the 5-D Itch total score', 'will be tested first. If results are statistically significant in favor of', 'CR845, testing with respect to the Skindex-10 total score will proceed', 'and be inferential. The proportion of patients achieving >4-point', 'improvement from baseline with respect to the weekly mean of the', 'daily 24-hour Worst Itching Intensity NRS at Week 12 of the Double-', 'blind Treatment Period will be tested only if the results of Skindex-1(', 'total score are statistically significant in favor of CR845.', 'Details and methods of analysis are found in Section 8.0 and will be', 'described further in the statistical analysis plan.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 16 of 95']"
14,page_15,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 15 of 92', 'CR845-CLIN3102', '2.0', 'Table of Contents', '1.0 Protocol Synopsis', '4', '2.0 Table of Contents', '15', '3.0 List of Abbreviations', '20', '4.0 Introduction', '21', '4.1', 'Background and Rationale', '21', '4.2', 'Clinical Experience', '22', '4.2.1', 'Overall Exposure', '22', '4.2.2', 'Safety in Hemodialysis Patients', '22', '4.2.3', 'Efficacy of CR845 in Hemodialysis Patients with Uremic Pruritus', '23', '4.2.4', 'Pharmacokinetics in Hemodialysis Patients', '24', '4.3', 'Summary of Potential Risks and Benefits', '25', '5.0 Objectives', '26', '6.0 Investigational Plan', '27', '6.1', 'Overall Study Design and Plan: Description', '27', '6.1.1', 'Double-blind Phase', '27', '6.1.1.1', 'Screening Visit', '27', '6.1.1.2', 'Run-in Period', '27', '6.1.1.3', 'Double-blind Treatment Period', '28', '6.1.1.4', 'Double-blind Discontinuation Period', '29', '6.1.2', 'Open-label Extension Phase', '30', '6.2', 'Selection of Study Population', '32', '6.2.1', 'Inclusion Criteria', '32', '6.2.2', 'Exclusion Criteria', '33', '6.3', 'Removal of Patients from Therapy or Assessment', '34', '6.3.1', 'Discontinuation of Individual Patients', '34', '6.3.2', 'Discontinuation or Suspension of Entire Study', '35', '6.4', 'Treatments', '36', '6.4.1', 'Treatments Administered', '36', '6.4.2', 'Identity of Investigational Product(s)', '36', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 17 of 95']"
15,page_16,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 16 of 92', 'CR845-CLIN3102', '6.4.2.1', 'Formulation of Study Drug', '36', '6.4.2.2', 'Packaging, Labeling, and Storage Stability of Study Drug', '37', '6.4.2.3', 'Individual Dose Labeling', '38', '6.4.3', 'Drug Accountability', '38', '6.4.4', 'Method of Assigning Patients to Treatment Groups', '38', '6.4.5', 'Preparation of CR845', '38', '6.4.6', 'Management of Missed Doses', '39', '6.4.7', 'Treatment Compliance', '39', '6.4.8', 'Blinding', '39', '6.4.9', 'Prior, Concomitant, and Prohibited Medications', '39', '6.4.9.1', 'Prior and Concomitant Medications', '39', '6.4.9.2', 'Restricted and Prohibited Medications', '39', '6.5', 'Study Assessments and Procedures', '40', '6.5.1', 'Schedule of Events for the Double-blind Phase', '40', '6.5.2', 'Schedule of Events for the Open-label Extension Phase', '44', '6.5.3', 'Efficacy Assessments', '48', '6.5.3.1', 'Worst Itching Intensity Numerical Rating Scale', '48', '6.5.3.2', 'Skindex-10 Scale', '48', '6.5.3.3', '5-D Itch Scale', '48', '6.5.3.4', 'Patient Global Impression of Change', '49', '6.5.4', 'Safety Assessments', '49', '6.5.4.1', 'Adverse Events', '49', '6.5.4.2', 'Structured Safety Evaluation', '53', '6.5.4.3', 'Physical Examination', '53', '6.5.4.4', 'Vital Signs', '54', '6.5.4.5', 'Electrocardiogram', '54', '6.5.4.6', 'Clinical Laboratory Tests', '54', '6.5.4.7', 'Contraception and Pregnancy', '54', '6.5.5', 'Additional Assessments', '55', '6.5.5.1', 'Inflammatory Biomarkers', '55', '6.5.5.2', 'Missed Dialysis Visits', '56', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 18 of 95']"
16,page_17,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 17 of 92', 'CR845-CLIN3102', '6.5.5.3', 'ESAs and IV Iron', '56', '6.5.5.4', 'Discontinuation Period Additional Assessments', '56', '7.0 Discussion and Justification of Study Design', '57', '7.1', 'Discussion of Study Design and Choice of Control Groups', '57', '7.2', 'Selection of Doses in the Study', '57', '7.3', 'Appropriateness of Measurements', '57', '8.0 Statistical Methods', '58', '8.1', 'General Considerations', '58', '8.2', 'Determination of Sample Size', '58', '8.3', 'Randomization', '59', '8.4', 'Interim Analysis', '60', '8.4.1', 'Sample Size Re-estimation', '60', '8.4.2', 'Safety Data Review', '61', '8.5', 'Analysis Populations', '61', '8.6', 'Statistical Summary and Analysis', '62', '8.6.1', 'Patient Disposition', '62', '8.6.2', 'Protocol Deviations', '62', '8.6.3', 'Demographic and Baseline Characteristics', '62', '8.6.4', 'Medical History', '62', '8.6.5', 'Prior and Concomitant Medications', '63', '8.6.6', 'Antipruritic Medication', '63', '8.7', 'Efficacy Analysis', '63', '8.7.1', 'Primary Efficacy Endpoint', '63', '8.7.2', 'Secondary Efficacy Endpoints', '65', '8.7.3', 'Hypothesis Testing Strategy', '66', '8.7.4', 'Additional Efficacy Endpoints', '67', '8.7.4.1', 'Itch-intensity Measures', '67', '8.7.4.2', 'Itch-related Quality-of-Life Measures', '67', '8.8', 'Safety Analysis', '68', '8.8.1', 'Exposure to Study Drug', '68', '8.8.2', 'Adverse Events', '69', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 19 of 95']"
17,page_18,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 18 of 92', 'CR845-CLIN3102', '8.8.3', 'Clinical Laboratory Evaluations', '70', '8.8.4', 'Vital Signs and ECGs', '70', '8.9', 'Additional Analyses', '72', '8.9.1', 'Inflammatory Biomarkers', '72', '8.9.2', 'Missed Dialysis Visits and Incidence of Infection', '72', '8.9.3', 'ESA and IV Iron', '72', '8.9.4', 'Discontinuation Period Additional Assessments', '72', '9.0 Quality Control and Quality Assurance', '74', '9.1', 'Study Monitoring Plan', '74', '9.2', 'Audits and Inspections', '74', '9.3', 'Data Collection, Validation, and Analysis', '75', '10.0 Ethics and Regulatory Compliance', '76', '10.1', 'Independent Ethics Committee or Institutional Review Board', '76', '10.2', 'Ethical Conduct of the Study', '76', '10.3', 'Informed Consent Process', '77', '10.4', 'Patient Confidentiality', '77', '11.0 Data Handling and Quality Assurance', '79', '12.0 Administrative Procedures', '80', '12.1', 'Protocol Adherence', '80', '12.2', 'Publication of Study Findings', '80', '13.0 References', '81', '14.0 Appendix', '83', '14.1', 'Appendix 1: New York Heart Association Classification of Heart Failure', '83', '14.2', 'Appendix 2: Worst Itching Intensity Numerical Rating Scale (NRS)', '84', '14.3', 'Appendix 3: Skindex-10 Scale', '85', '14.4', 'Appendix 4: 5-D Itch Scale', '86', '14.5', 'Appendix 5: Patient Global Impression of Change', '88', '14.6', 'Appendix 6: Short Opiate Withdrawal Scale', '89', '14.7', 'Appendix 7: Objective Opiate Withdrawal Scale', '90', '15.0 Statistical Appendix', '91', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 20 of 95']"
18,page_19,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 19 of 92', 'CR845-CLIN3102', 'LIST OF TABLES', 'Table 1.', 'Restricted and Prohibited Medications', '40', 'Table 2.', 'Schedule of Events: Double-blind Phase', '41', 'Table 3.', 'Schedule of Events: Open-label Extension Phase', '45', 'Table 4.', 'Power as a Function of Effect Size (N = 175 per arm)', '59', 'Table 5.', 'Sample Size as a Function of Odds Ratio (90% Power)', '59', 'Table 6.', 'Criteria Used to Identify Clinically Notable Vital Sign Abnormalities 71', 'LIST OF FIGURES', 'Figure 1.', 'CR845-CLIN3102 Study Schematic', '31', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 21 of 95']"
19,page_20,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 20 of 92', 'CR845-CLIN3102', '3.0', 'List of Abbreviations', 'AESI', 'adverse event of special interest', 'ATC', 'Anatomical Therapeutic Chemical', 'CFR', 'Code of Federal Regulations', 'CI', 'confidence interval', 'CNS', 'central nervous system', 'ECG', 'electrocardiogram', 'eCRF', 'electronic case report form', 'ESA', 'erythropoiesis-stimulating agent', 'ESRD', 'end-stage renal disease', 'FDA', 'Food and Drug Administration', 'GCP', 'Good Clinical Practice', 'H', ""above the laboratory parameter's reference range"", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation', 'IDMC', 'Independent Data Monitoring Committee', 'IL', 'interleukin', 'IND', 'Investigational New Drug', 'IRB', 'Institutional Review Board', 'ISF', 'Investigator Site File', 'IV', 'intravenous', 'IVRS/IWRS', 'interactive voice or web response system', 'KOR', 'kappa-opioid receptor', 'L', ""below the laboratory parameter's reference range"", 'LS', 'least squares', 'MAR', 'missing at random', 'MCMC', 'Markov Chain Monte Carlo', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MI', 'multiple imputation', 'MMRM', 'mixed effects model with repeated measures', 'MNAR', 'missing not at random', 'N', ""within the laboratory parameter's reference range"", 'NRS', 'numerical rating scale', 'OOWS', 'Objective Opiate Withdrawal Scale', 'PRO', 'patient-reported outcome', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'SE', 'standard error', 'ShOWS', 'Short Opiate Withdrawal Scale', 'SOC', 'System Organ Class', 'TEAE', 'treatment-emergent adverse event', 'ULN', 'upper limit of normal', 'Abbreviations that occur only in tables or figures are defined within the appropriate table or figure.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 22 of 95']"
20,page_21,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 21 of 92', 'CR845-CLIN3102', '4.0', 'Introduction', '4.1', 'Background and Rationale', 'CR845 is a kappa-opioid receptor (KOR) agonist with a peripheral mechanism of action', 'being developed by Cara Therapeutics, Inc. (designated as Cara Therapeutics or Sponsor', 'in this protocol) as a novel therapeutic agent for the symptomatic relief of acute and', 'chronic pain and pruritus.', 'Opioid receptors are involved in the modulation of itch and pain signals and consist of', '3 subtypes: mu, kappa, and delta. These receptor subtypes are found in the central', 'nervous system (CNS), in peripheral nervous system tissues, such as skin and viscera,', ""and in the immune system (see Investigator's Brochure for references and further details)."", 'CR845 was designed to activate KORs located primarily in the peripheral nervous', 'system, which are known to modulate itch, pain, and inflammatory signals, without', 'producing the side effects associated with the activation of mu-opioid receptors, such as', 'respiratory depression, abuse liability, and constipation.', 'CR845 is a potent and selective KOR agonist with no activity at mu- and delta-opioid', ""receptors or other receptors, ion channels, or transporters. CR845's unique peptidic"", 'structure significantly differs from other small molecule KOR agonists developed to date,', 'which, for the most part, are CNS-active. Being a hydrophilic peptide, CR845 has', 'limited membrane permeability by passive diffusion, which limits its access to the CNS.', 'Since CR845 does not activate receptors other than KORs and does not readily enter the', 'CNS, it is expected to be safer and better tolerated than other opioid agonists, including', 'kappa agonists.', 'Uremic pruritus is a chronic, unremitting, and highly bothersome condition in patients', 'with chronic kidney disease that adversely affects sleep, mood, and ability to socialize', '[Kumagai 2010]. Patients with uremic pruritus frequently exhibit considerable', 'mechanical skin damage because of continuous scratching with excoriations,', 'superimposed infections, and chronic lesions of prurigo nodularis or skin lichenification', 'often occurring. The mechanical skin damage can become an additional source of', 'itching. Consequently, these patients are at increased risk of related morbidities', 'associated with infection, eg, cellulitis, sepsis, bacteremia, cutaneous infections, and', 'infections of the dialysis access, and are at higher mortality risk (>15%)', '[Pisoni 2006; Narita 2006]. Large multinational studies (Dialysis Outcomes and Practice', 'Patterns) and studies based in the United States have demonstrated that approximately', '30 to 40% of hemodialysis patients have moderate-to-severe pruritus. There are no', 'approved treatments for this condition in the United States and current off-label therapies', 'are unable to successfully treat uremic pruritus.', 'Although the pathophysiology of moderate-to-severe pruritus in hemodialysis patients is', 'not well understood, there is increasing evidence that it is likely multifactorial and that an', 'immune system dysfunction (including elevated proinflammatory activity) and imbalance', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 23 of 95']"
21,page_22,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 22 of 92', 'CR845-CLIN3102', 'in the endogenous opioid system (with over-expression of mu-opioid receptors in dermal', 'cells and lymphocytes and concomitant downregulation of KORs) are involved', '[Kimmel 2006; Narita 2006; Phan 2012; Patel 2007; Mettang 2002; Tey 2011].', 'Based on nonclinical pharmacological studies, it was anticipated that CR845 will produce', ""a combined anti-itch, and anti-inflammatory effect (see Investigator's Brochure for"", 'details), which could provide significant relief of itch in hemodialysis patients.', 'In nonclinical studies, CR845 has been shown to exhibit antipruritic and', ""anti-inflammatory properties [Investigator's Brochure]. Thus, CR845 is intended to"", 'reduce the severity of itching in hemodialysis patients and thereby decrease the likelihood', 'of developing additional serious conditions associated with uremic pruritus.', '4.2', 'Clinical Experience', '4.2.1', 'Overall Exposure', 'As of the writing of this protocol, the intravenous (IV) formulation of CR845 has been', 'evaluated in 722 patients and healthy volunteers across eight Phase 1 studies (including', '2 studies conducted in Japan), three Phase 2 studies for the relief of moderate-to-severe,', 'acute postoperative pain, and two Phase 2 studies for the relief of moderate-to-severe', 'pruritus in hemodialysis patients. In the United States, CR845 has been evaluated both as', 'an IV bolus and a 15-minute infusion of single or repeated doses ranging from', '0.5 to 40 mcg/kg.', 'Of the patients exposed to IV CR845 to date, 213 hemodialysis patients (127 males and', '86 females) have received single or repeated IV injections of CR845 doses (for up to', '8 weeks) ranging from 0.5 to 6 mcg/kg across two Phase 1 studies and two Phase 2 safety', 'and efficacy studies.', ""The most current information is contained in the current Investigator's Brochure."", '4.2.2', 'Safety in Hemodialysis Patients', 'A review of the aggregate safety data shows that CR845 was well tolerated in', 'hemodialysis patients when administered after each dialysis session for up to 8 weeks at', 'IV doses ranging from 0.5 mcg/kg to 6 mcg/kg. Although patients exposed to CR845', 'reported more adverse events compared with placebo patients, most events were mild or', 'moderate in nature. Generally mild, transient paresthesias (facial tingling) and/or', 'hypoesthesias (in different anatomic locations), mostly on the first week of dosing, as', 'well as headache, dizziness, and somnolence, were the most frequently reported adverse', 'events associated with CR845 administration. Of note, side effects (eg, dysphoria and', 'hallucinations) commonly associated with centrally-acting kappa opioids were not', 'reported in patients exposed to CR845. Consistent with its lack of affinity for mu-opioid', 'receptors, CR845 did not cause euphoria, respiratory depression, or reduction in oxygen', 'saturation.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 24 of 95']"
22,page_23,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 23 of 92', 'CR845-CLIN3102', 'CR845-CLIN2101 (Part A) evaluated the safety, pharmacokinetics, and efficacy of', 'repeated IV doses of CR845 compared to placebo over an 8-week treatment period in', '174 hemodialysis patients. This study is the longest treatment period evaluated to date in', 'hemodialysis patients and no clinically important or significant safety findings related to', 'CR845 were noted. As expected with patients on hemodialysis, a significant number of', 'the reported serious adverse events (SAEs) were considered not treatment-related, but', 'related to the disease and/or comorbid conditions. There were 31 (17.8%) of 174 patients', 'randomized and treated in the study who had treatment-emergent SAEs. Of the 31 SAE', 'reports, 4 (9%) occurred in 45 placebo-treated patients and 27 (21%) in', '129 CR845-treated patients. Only 1 SAE of mental status changes (moderate in severity)', 'in a patient who received CR845 1.5 mcg/kg IV was considered by the Investigator to be', ""probably related to study drug. However, based on the Sponsor's medical review, an"", 'alternate etiology of urgent/emergent hypertension offers a more plausible explanation', 'for the acute change in mental status. There were 4 patient deaths (2.3%) in the study, all', 'of which were considered not related to the study drug.', 'In patients with normal renal function, CR845 can cause free-water diuresis (aquaresis)', 'and increased serum sodium. However, as would be expected in patients undergoing', 'dialysis in whom there are few functioning nephrons, there was no evidence of aquaresis', 'or significant increases in serum sodium concentrations. There were no adverse trends in', 'clinical chemistry or hematology values (drawn pre-dialysis), including, no apparent', 'differences between the placebo and CR845 groups in serum sodium. There were no', 'discernable differences between treatment groups in vital sign results. Of particular note,', 'among patients receiving CR845, there was no apparent reduction in blood pressure or', 'respiratory rate following dosing.', ""Adverse event summary tables can be found in the Investigator's Brochure, with further"", 'details of the safety profile of CR845.', '4.2.3', 'Efficacy of CR845 in Hemodialysis Patients with Uremic Pruritus', 'The efficacy of CR845 in uremic pruritus was evaluated in two Phase 2, randomized,', 'double-blind, placebo-controlled studies (CR845-CLIN2005 [Part B and', 'CR845-CLIN2101 [Part A]).', 'CR845-CLIN2005 (Part B) included 65 hemodialysis patients with moderate-to-severe', 'uremic pruritus who received either IV CR845 1.0 mcg/kg (n=33) or placebo (n=32)', '3 times per week for 2 weeks, after each hemodialysis session. CR845 significantly', 'decreased itching intensity compared with placebo (p=0.016), as measured by a visual', 'analog scale (VAS) and significantly improved quality of life related to itching', ""(Skindex-10 Scale) (see Investigator's Brochure for details). Furthermore,"", 'CR845-treated patients exhibited statistically significant reductions in both daytime', '(p=0.03) and nighttime (p=0.007) worst itching scores compared with placebo, and the', 'reduction in itching intensity scores was similar on dialysis and nondialysis days. The', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 25 of 95']"
23,page_24,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 24 of 92', 'CR845-CLIN3102', 'mean change from baseline VAS curves over time showed numerical separation between', 'the treatment groups within the first week of treatment.', 'CR845-CLIN2101 (Part A) evaluated the safety, pharmacokinetics, and efficacy of', 'repeated IV doses of CR845 compared to placebo over an 8-week treatment period in', '174 hemodialysis patients experiencing moderate-to-severe uremic pruritus daily or', 'near-daily for 4.4 years on average. The study was conducted at 33 dialysis centers and', 'assessed the effect of 3 doses of CR845 (ie, 0.5 mcg/kg, n=44; 1 mcg/kg, n=41 and', '1.5 mcg/kg, n=44) or placebo (n=45) administered at the end of each dialysis session', '(ie, 3 times/week). The primary efficacy endpoint for Study CR845-CLIN2101 (Part A)', 'was based on itch intensity measurement and defined as the change from a 1-week', 'baseline recorded prior to the start of study drug to the last week of the 8-week treatment', 'period with respect to the weekly mean of the daily 24-hour Worst Itching Intensity', 'numerical rating scale (NRS) score. The least squares (LS) mean (=standard error [SE])', 'treatment group difference from placebo at Week 8 across all CR845 doses', 'was - -1.3 (=0.41) (95% confidence interval [CI]: -2.1 to -0.5) (p=0.002) with an average', 'NRS score reduction from baseline of -3.2 (=0.22) (LS mean SE) and 95% CI ranging', 'from -3.7 to -2.8. Examination of the individual CR845 dose group results for the Full', 'Analysis Population indicates that a substantial improvement over placebo was observed', 'with all 3 doses. These differences from placebo were statistically significant for the', 'lower dose group of 0.5 mcg/kg (p<0.001) and the 1.5 mcg/kg group (p=0.019), with an', 'effect size estimated as 0.82, 0.39, and 0.62 for the 0.5, 1.0, and 1.5 mcg/kg doses,', 'respectively. Average reduction from baseline (LS mean SE) ranged from -2.8 (=0.38)', 'in the 1.0 mcg/kg dose group (95% CI ranging from -3.5 to -2.0) to -3.8 (=0.38) in the', '0.5 mcg/kg dose group (95% CI ranging from -4.5 to -3.1).', '4.2.4', 'Pharmacokinetics in Hemodialysis Patients', 'CR845 is eliminated primarily through the kidney and no major metabolites have been', 'identified in humans. Consequently, total body clearance of CR845 in patients with', 'severe renal impairment is reduced relative to healthy, matched, control patients', '(CR845-CLIN1005) such that plasma levels of CR845 remain relatively constant until', 'cleared during dialysis in hemodialysis patients (CR845-CLIN1003 and', 'CR845-CLIN2005 [Part A]). Half-life ranges between 26 and 34 hours in hemodialysis', 'patients compared to a typical range of 2 to 3 hours in patients with normal renal', 'function. Thus, lower doses of CR845 can be administered at a less frequent interval in', 'hemodialysis patients to achieve the same or higher overall exposure compared to', 'individuals with normal renal function. Based on this pharmacokinetic profile, CR845', 'does not need to be administered more than 3 times a week after each hemodialysis', 'session, which is convenient for this patient population and ensures treatment compliance', 'in a population already burdened with complex medication schedules.', 'The pharmacokinetic profile of repeat-dose CR845 was studied in 24 hemodialysis', 'patients who received doses of 0.5, 1.0, or 2.5 mcg/kg 3 times per week for 1 week', '(CR845-CLIN2005 Part A]). In this study, there were dose-proportional increases in', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 26 of 95']"
24,page_25,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 25 of 92', 'CR845-CLIN3102', 'maximum concentration and area under the curve, and minimal to no accumulation with', ""repeat doses due to clearance of the drug by hemodialysis (see Investigator's Brochure"", 'for details).', '4.3', 'Summary of Potential Risks and Benefits', 'During preclinical development, no specific safety findings to preclude the use of CR845', 'in humans were observed. During early clinical development, IV CR845 was', 'administered to healthy volunteers; patients with mild, moderate, or severe renal', 'impairment, including end-stage renal disease (ESRD) and hemodialysis patients;', 'recreational poly-drug users; and postsurgical patients. The effects of CR845 have been', 'shown to be in line with the underlying pharmacological mechanism of KOR activity.', 'Consistent with the nonclinical abuse liability studies conducted to date, the results of an', 'abuse-potential study in humans indicated that CR845 appears to present a low risk for', 'abuse potential in humans in comparison to currently clinically used opioids.', 'Overall, tingling/numbness, dizziness, fatigue and/or drowsiness/somnolence have been', 'the most common adverse events. Precaution is recommended in the operation of', 'machinery for patients who experience dizziness, fatigue, and/or drowsiness/somnolence.', 'This is described in the informed consent form (ICF), as appropriate, and will be', 'discussed with each patient prior to initiation of the study. In general, CR845 appeared to', 'be well tolerated in both single- and repeat-dose clinical studies, which support continued', 'study and development of this compound.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 27 of 95']"
25,page_26,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 26 of 92', 'CR845-CLIN3102', '5.0', 'Objectives', 'Primary Objective', 'To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared to', 'placebo in reducing the intensity of itch in hemodialysis patients with', 'moderate-to-severe pruritus.', 'Secondary Objectives', 'To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared', 'to', 'placebo in improving itch-related quality-of-life measures in hemodialysis', 'patients with moderate-to-severe pruritus.', 'To evaluate the safety of IV CR845 at a dose of 0.5 mcg/kg in hemodialysis', 'patients with moderate-to-severe pruritus.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 28 of 95']"
26,page_27,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 27 of 92', 'CR845-CLIN3102', '6.0', 'Investigational Plan', '6.1', 'Overall Study Design and Plan: Description', 'This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the', 'safety and efficacy of IV CR845 at a dose of 0.5 mcg/kg administered after each dialysis', 'session. The study includes a Double-blind Phase and an Open-label Extension Phase.', 'CR845 will be evaluated relative to placebo over a 12-week Double-blind Treatment', 'Period in hemodialysis patients with moderate-to-severe pruritus followed by a 2-week', 'monitored Discontinuation Period. At the end of the Discontinuation Period, patients', 'who received at least 30 doses of study drug during the 12-week Double-blind Treatment', 'Period will have the option to receive open-label CR845 for an additional 52 weeks.', '6.1.1', 'Double-blind Phase', 'The Double-blind Phase of the study will consist of a Screening Visit, a 7-day Run-in', 'Period, a 12-week Double-blind Treatment Period, and a 2-week Discontinuation Period.', 'Informed consent will be obtained prior to performing any study-specific procedures.', 'The Screening Visit will occur within 7 to 28 days prior to randomization in order to', 'assess eligibility. The Screening Visit can be conducted during the Run-in Period at the', 'discretion of the Investigator.', '6.1.1.1', 'Screening Visit', 'During the Screening Visit, patients will sign the Informed Consent, and will be', 'evaluated for eligibility by assessment of inclusion/exclusion criteria, medical history,', 'physical examination, prescription dry body weight, pre-dialysis 12-lead', 'electrocardiogram, pre-dialysis vital signs, pre-dialysis hematology and serum chemistry,', 'serum pregnancy test for females of childbearing potential, adverse events, and ESA and', 'IV iron doses, and prior medications.', '6.1.1.2', 'Run-in Period', 'Eligible patients will complete a 7-day Run-in Period during the week prior to', 'randomization to confirm eligibility, starting on the first dialysis session of that week', '(ie, Monday for patients on a Monday-Wednesday-Friday dialysis schedule or Tuesday', 'for patients on a Tuesday-Thursday-Saturday dialysis schedule). The purpose of the', 'Run-in Period will be to confirm that each patient has moderate-to-severe pruritus', '(ie, weekly average score >4), as measured by the 24-hour Worst Itching Intensity NRS,', 'and to establish a baseline itch intensity. These criteria for eligibility should not be', ""communicated to the patients. This period will also be used to record each patient's use"", 'of itch medications.', 'During the first visit of the Run-in Period, patients will be trained on completion of the', '24-hour Worst Itching Intensity NRS scale and will start the reporting of their Worst', 'Itching Intensity NRS daily score. For consistency, patients will be requested to', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 29 of 95']"
27,page_28,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 28 of 92', 'CR845-CLIN3102', 'complete the NRS worksheets (either at home or in the dialysis unit, as required) at a', 'similar time of day around the normal start time of their dialysis.', 'Patients will also be trained on other itch-related patient-reported outcome (PRO) and', 'patient health assessment worksheets during the Run-in Period or on Day 1 of the', 'Double-blind Treatment Period.', 'A Structured Safety Evaluation will be performed during the Run-in Period (preferably', 'on Wednesday/Thursday). The Structured Safety Evaluation is performed by study staff', 'using a list of specific signs/symptoms (eg, mental status change, falls, gait disturbance).', '6.1.1.3', 'Double-blind Treatment Period', 'If patients continue to meet all inclusion and no exclusion criteria at the end of the 7-day', 'Run-in Period, they will be randomized into the Double-blind Treatment Period in a', '1:1 ratio to receive either IV CR845 0.5 mcg/kg or placebo. Patients will be stratified', 'according to their use or non-use of concomitant medications to treat their itch during the', 'week prior to randomization (Run-in Period) as well as the presence or absence of', 'specific medical conditions.', 'Day 1 of the Double-blind Treatment Period will be defined as the day of administration', 'of the first dose of study drug and will occur on the first dialysis session day of the first', 'treatment week (ie, Monday for patients on a Monday-Wednesday-Friday dialysis', 'schedule or Tuesday for patients on a Tuesday-Thursday-Saturday dialysis schedule).', 'Patients will be administered CR845 or matched placebo as an IV bolus after the end of', 'each dialysis session during the 12-week Double-blind Treatment Period so that each', 'patient will receive CR845 or placebo 3 times weekly for a total of up to 36 doses.', 'During the Double-blind Treatment Period, patients will continue to report their Worst', 'Itching Intensity NRS score on a daily basis, covering the previous 24 hours. In addition,', 'during selected study visits, they will complete other PRO measures (Skindex-10 Scale,', '5-D Itch Scale, and Patient Global Impression of Change). Patients will be instructed to', 'record patient-reported outcome measurements, including Worst Itching Intensity NRS', 'scores, at a similar time of day, whether in the dialysis unit (on dialysis days) or at home', '(on non-dialysis days).', 'Blood samples for inflammatory biomarkers will be collected for all randomized patients', 'prior to dialysis on Day 1 and prior to the last dialysis at the End-of-Treatment Visit for', 'the Double-blind Treatment Period (Day 85).', 'Clinical laboratory tests and vital signs will be monitored periodically, and adverse', 'events and concomitant medications will be continuously recorded starting at the', 'Screening Visit until the end of the Discontinuation Period or Early Termination Visit.', 'Electrocardiograms (ECGs) will be monitored at Screening Visit and Day 85 or Early', 'Termination Visit.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 30 of 95']"
28,page_29,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 29 of 92', 'CR845-CLIN3102', 'The number and reason(s) for missed dialysis as well as the use of antipruritic', 'medications, iron, and erythropoiesis-stimulating agents (ESAs) will be recorded', 'throughout the study.', 'A Structured Safety Evaluation will be performed weekly (preferably on', 'Wednesday/Thursday) during the Double-blind Treatment Period. The Structured Safety', 'Evaluation is performed by study staff using a list of specific signs/symptoms (eg, mental', 'status change, falls, gait disturbance).', '6.1.1.4', 'Double-blind Discontinuation Period', 'The Double-blind Treatment Period will be followed by a 2-week Discontinuation', 'Period, during which no study drug will be administered and patients will be monitored', 'for potential physical dependence, as follows:', 'Daily patient completion of the Short Opiate Withdrawal Scale', '(ShOWS-Gossop 1990) (paper worksheet to be filled by each patient at home on', 'nondialysis days and at the dialysis unit on dialysis days at similar time of the day', 'for a given patient) (see worksheet in Appendix 6, Section 14.6)', 'Completion of an Objective Opiate Withdrawal Scale (OOWS) worksheet', '(Handelsman 1987) by a trained observer at each dialysis visit (ie, 3 times a week)', '(see worksheet in Appendix 7, Section 14.7) (training of observer will be', 'recorded)', 'Recording of adverse events, medication used, body temperature, and vital signs', 'at each dialysis visit.', 'Measurements will be taken starting at the end of the Treatment Period (Day 85) and then', 'at each dialysis visit for up to 2 weeks following study drug discontinuation until Day 98', '(Table 2).', 'During this Discontinuation Period, at each dialysis visit, patients will be asked to', 'continue to report their daily Worst Itching Intensity NRS score over the previous', '24 hours. In order to minimize bias, the OOWS and ShOWS will be introduced to the', 'patients as health-assessment scales.', 'On the day of a dialysis visit, the OOWS and the ShOWS will be completed during the', 'first hour (+1-hour window allowed) of dialysis so that dialysis-associated patient fatigue', 'should minimally interfere with the completion of the scales. Double-blind study drug', 'treatment assignment will remain blinded throughout the course of the Discontinuation', 'Period. For patients who withdraw from the Double-blind Treatment Period early, every', 'attempt will be made to conduct the 2-week Discontinuation Period.', 'A Structured Safety Evaluation will be performed weekly (preferably on', 'Wednesday/Thursday) during the Discontinuation Period. The Structured Safety', 'Evaluation is performed by study staff using a list of specific signs/symptoms (eg, mental', 'status change, falls, gait disturbance).', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 31 of 95']"
29,page_30,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 30 of 92', 'CR845-CLIN3102', '6.1.2', 'Open-label Extension Phase', 'Patients who received at least 30 doses of study drug (either placebo or active) during the', '12-week Double-blind Treatment Period and continue to meet other eligibility criteria', 'will have the option to receive open-label CR845 for an additional 52 weeks. The Open-', 'label Extension Phase will be comprised of the Open-label Treatment Period and the Follow-up', 'Period. The first visit and first dosing for the Open-label Extension Phase of the study', 'will occur during the week (+1-week window) following the Discontinuation Period.', 'Each patient will receive CR845 at a dose of 0.5 mcg/kg after each dialysis session,', '3 times per week for up to 52 weeks, whether they had been previously administered', 'placebo or CR845. Prescription dry weight will be recorded every 12 weeks; if there is a', '>10% change from the previous recorded dry weight, then the CR845 dose will be', 'adjusted.', 'During selected study weeks, patients will complete the 5-D Itch Scale.', 'Clinical laboratory tests, vital signs, adverse events, and concomitant medications will be', 'monitored throughout the Open-label Treatment Period. Blood samples for inflammatory', 'biomarkers will be collected periodically until the End-of-Treatment or Early', 'Termination Visit. An electrocardiogram will be monitored at the End-of-Treatment or', 'Early Termination Visit.', 'The number and reason(s) for missed dialysis will be recorded throughout the study. Use', 'of antipruritic medications, iron, and ESAs will be recorded throughout the Open-label', 'Treatment Period.', 'The last dose of open-label study drug will be administered at the last dialysis visit in', 'Week 52. A final safety Follow-up Visit will be conducted 7-10 days after the', 'End-of-Treatment/Early Termination Visit.', 'The study schematic is shown in Figure 1.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 32 of 95']"
30,page_31,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 31 of 92', 'CR845-CLIN3102', 'Figure 1.', 'CR845-CLIN3102 Study Schematic', 'Double-blind Phase', 'Informed', 'Screening Visit', 'Run-in Period', 'consent', 'Days -28 to -7', 'Days -7 to 1', 'Day 1 of', 'Double-blind', 'End of Double-', 'Discontinuation', 'Double-blind', 'Treatment', 'blind Treatment/', 'Period', 'Treatment', 'Period Dosing', 'Early', 'Period', 'with study drug', 'Termination', 'Day 85 to', 'Randomization', 'for 12 weeks', 'Day 85', 'Day 98', 'First dose of', 'First dialysis after', 'up to 14 days', 'double-blind', 'last dose of study', 'from End of', 'study drug', 'drug', 'Treatment/', 'Early', 'Termination', 'Open-label Extension Phase', 'Day 1 up to 1', 'Open-label', 'End of Open-label', 'Open-label', 'week following', 'Treatment Period', 'Treatment/Early', 'Follow-up/Early', 'Discontinuation', 'Dosing of', 'Termination', 'Termination', 'Period', 'open-label CR845', 'First dialysis after last', '7 to 10 days from', 'First dose of', 'for up to 52 weeks', 'dose of open-label', 'End of Treatment/', 'open-label CR845', 'CR845', 'Early Termination', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 33 of 95']"
31,page_32,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 32 of 92', 'CR845-CLIN3102', '6.2', 'Selection of Study Population', 'Patients with ESRD receiving hemodialysis 3 times a week and experiencing', 'moderate-to-severe pruritus will be considered for participation in this study.', 'A screening log of potential study candidates will be maintained at each study site.', 'Patients providing informed consent will be screened for inclusion in the study. All', 'eligibility criteria must be met before a patient is randomized.', 'Rescreening will be considered on an individual patient basis and must first be approved', 'by the Sponsor.', '6.2.1', 'Inclusion Criteria', 'To be eligible for inclusion into the Double-blind Phase of the study, a patient must meet', 'the following criteria:', '1. Willing and able to provide written informed consent prior to participating in this', 'study;', '2. Able to communicate clearly with the Investigator and staff, able to understand the', 'study procedures, and able and willing to comply with the study requirements;', '3. Male or female 18 years of age or older;', '4. Has ESRD and has been on hemodialysis 3 times per week for at least 3 months', 'prior to the start of screening;', 'Note 1: Patients who require an occasional additional dialysis treatment to', 'manage fluid overload may be enrolled as long as it is anticipated that no more', 'than 1 such treatment will be required in any given week.', 'Note 2: Patients receiving in-home hemodialysis may participate as long as they', 'have switched to in-center hemodialysis at least 2 weeks prior to screening and', 'plan to remain on in-center hemodialysis for the duration of the study.', '5. If female, is not pregnant or nursing during any period of the study;', '6. If female:', 'a.', 'Is surgically sterile; or', 'b. Has been amenorrhoeic for at least 1 year and is over the age of 55 years;', 'or', 'c. Has a negative serum pregnancy test at screening and agrees to use', 'acceptable contraceptive measures (eg, hormonal contraceptives, barrier', 'with spermicide, intrauterine device, vasectomized partner, or abstinence)', 'from the time of informed consent until 7 days after the last dose of study', 'drug;', '7. If male, agrees not to donate sperm after the first dose of study drug until 7 days', 'after the last dose of study drug, and agrees to use a condom with spermicide or', 'abstain from heterosexual intercourse during the study until 7 days after the last', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 34 of 95']"
32,page_33,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 33 of 92', 'CR845-CLIN3102', 'dose of study drug. (Note: No restrictions are required for a vasectomized male', 'provided his vasectomy was performed >4 months prior to screening);', '8. Has a prescription dry body weight between 40.0 and 135.0 kg, inclusive;', '9.', 'Has at least 2 single-pool Kt/V measurements 1.2, or at least 2 urea reduction', 'ratio measurements >65%, or 1 single-pool Kt/V measurement >1.2 and 1 urea', 'reduction ratio measurement >65% on different dialysis days during the 3 months', 'period prior to screening;', '10. Prior to randomization:', 'a.', 'Has completed at least 4 Worst Itching Intensity NRS worksheets from the', 'start of the 7-day Run-in Period up to and including the pre-randomization', 'assessment on Day 1;', 'b. Has a mean baseline Worst Itching Intensity NRS score >4, defined as the', 'average of all non-missing scores reported from the start of the 7-day', 'Run-in Period up to and including the pre-randomization assessment on', 'Day 1.', 'To be eligible for inclusion into the Open-label Extension Phase of the study, each', 'patient will have to fulfill the additional following criteria at the time of entry into', 'the Open-label Extension Phase:', '11. Has received at least 30 doses of the planned 36 doses of study drug during the', 'Double-blind Phase of this study;', '12. Has a prescription dry body weight >40 kg;', '13. Continues to meet inclusion criteria 1 through 7.', '6.2.2', 'Exclusion Criteria', 'A patient will be excluded from the Double-blind Phase of the study if any of the', 'following criteria are met:', '1.', 'Known noncompliance with dialysis treatment that in the opinion of the', 'investigator would impede completion or validity of the study;', '2. Scheduled to receive a kidney transplant during the study;', '3. Known history of allergic reaction to opiates, such as hives (Note: side effects', 'related to the use of opioids, such as constipation or nausea, would not exclude', 'patients from the study);', '4. Has a concomitant disease or a history of any medical condition that, in the', 'opinion of the Investigator, could pose undue risk to the patient, impede', 'completion of the study procedures, or would compromise the validity of the', 'study measurements, including, but not limited to:', 'a.', 'Known or suspected history of alcohol, narcotic, or other drug abuse, or', 'substance dependence within 12 months prior to screening;', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 35 of 95']"
33,page_34,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 34 of 92', 'CR845-CLIN3102', 'b. Significant systolic or diastolic heart failure (eg, New York Heart', 'Association Class IV congestive heart failure [Appendix 1, Section 14.1]);', 'C. Severe mental illness or cognitive impairment (eg, dementia);', 'd. Any other relevant acute or chronic medical or neuropsychiatric condition', 'within 3 months prior to screening (eg, diagnosis of encephalopathy, coma,', 'delirium);', '5. New or change of treatment received for itch including antihistamines and', 'corticosteroids (oral, IV, or topical) within 14 days prior to screening;', '6. New or change of prescription for opioids, gabapentin, or pregabalin within', '14 days prior to screening;', '7. Received another investigational drug within 30 days prior to the start of', 'screening or is planning to participate in another clinical study while enrolled in', 'this study;', '8. In the opinion of the Investigator has pruritus attributed to a cause other than', 'ESRD or its complications (eg, patients with concomitant pruritic dermatological', 'disease or cholestatic liver disease) (Note: Patients whose pruritus is attributed to', 'ESRD complications, such as hyperparathyroidism, hyperphosphatemia, anemia,', 'or the dialysis procedure or prescription may be enrolled);', '9. Has localized itch restricted to the palms of the hands;', '10. Has pruritus only during the dialysis session (by patient report);', '11. Is receiving ongoing ultraviolet B and anticipates receiving such treatment during', 'the study;', '12. Participated in a previous clinical study with CR845.', 'A patient will be excluded from the Open-label Extension Phase of the study if any of', 'the additional following criteria are met at the time of entry into the Open-label', 'Extension Phase:', '13. Completed the Double-blind Phase of this study but exhibited adverse events', 'during the course of the Treatment Period that may preclude continued exposure', 'to the study drug;', '14. Was noncompliant with protocol procedures during the Double-blind Phase of', 'this study which is indicative of an inability to follow protocol procedures;', '15. Has developed a concomitant disease or any medical condition that, in the opinion', 'of the Investigator, could pose undue risk to the patient, impede completion of the', 'study procedures, or would compromise the validity of the study measurements.', '6.3', 'Removal of Patients from Therapy or Assessment', '6.3.1', 'Discontinuation of Individual Patients', 'A patient may withdraw from the study at any time at his/her own request for any reason', 'without prejudice to future medical care by the physician or at the institution.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 36 of 95']"
34,page_35,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 35 of 92', 'CR845-CLIN3102', 'A patient may be withdrawn at any time due to the following reasons:', '1. At the discretion of the Investigator or the Sponsor for safety, behavioral,', 'compliance, or administrative reasons;', '2. If a patient misses 3 consecutive doses either on Week 11 or Week 12 of the', 'Double-blind Treatment Period (these patients may still be eligible for the', 'Open-label Phase at the discretion of the Investigator in consultation with the', 'Sponsor).', '3. If patient misses 6 consecutive doses at any time;', '4.', 'At the discretion of the Sponsor/Medical Monitor, if a patient receives a', 'prohibited concomitant medication according to Table 1.', '5. Any patient who becomes pregnant during treatment must be withdrawn from', 'the study (see Section 6.5.4.7).', 'Whenever possible, withdrawal of a patient from study drug by the Investigator should be', 'discussed with the Medical Monitor before the patient stops study drug.', 'If study drug is discontinued, regardless of the reason, an Early Termination Visit should', 'be completed at the first dialysis after the last dose of study drug or, if not feasible during', 'that timeframe, as soon as feasible. If at all possible, a monitored 2-week Discontinuation', 'Period is to be completed after the Early Termination Visit in the Double-blind Phase.', 'Although a patient will not be obliged to give a reason for withdrawing prematurely, the', 'Investigator must make a reasonable effort to obtain the reason while fully respecting the', ""patient's rights. The reason(s) for termination and date of stopping study drug must be"", 'recorded on the electronic case report form (eCRF) and source documents.', 'If a patient discontinues early due to an adverse event, the event will be followed until', 'resolution, the patient returns to baseline status, the condition stabilizes, or the patient is', 'lost to follow-up.', 'A patient will be considered lost to follow-up when no response is received from the', 'patient after at least 3 documented attempts to contact the patient over a minimum time of', '2 weeks by the study site.', 'If the patient withdraws consent for disclosure of future information, the Sponsor may', 'retain and continue to use any data collected before such a withdrawal of consent.', 'Patients who discontinue after the administration of the first dose of study drug will not be', 'replaced.', '6.3.2', 'Discontinuation or Suspension of Entire Study', 'The Sponsor may suspend or terminate the study or part of the study at any time for any', 'reason. If the study is suspended or terminated, the Sponsor will ensure that applicable', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 37 of 95']"
35,page_36,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 36 of 92', 'CR845-CLIN3102', 'regulatory agencies and Institutional Review Boards (IRBs)/Independent Ethics', 'Committees are notified, as appropriate.', 'Should the study be closed prematurely, all study materials (eg, completed, partially', 'completed, and blank eCRFs, as well as study drug) must be returned to the Sponsor or', 'destroyed at the site according to instructions which will be provided by the Sponsor, as', 'applicable.', '6.4', 'Treatments', 'Additional information on the study drug and its preparation, administration, storage,', 'supply, disposition, and accountability can be found in the Pharmacy Section of the', 'Investigator Site File (ISF).', '6.4.1', 'Treatments Administered', 'The study drug will be dispensed by qualified staff members who have received training', 'on study drug handling and administration.', 'Patients will receive IV CR845 at a dose of 0.5 mcg/kg or placebo after each dialysis', 'session, generally 3 times per week for up to 64 weeks (ie, 12 weeks double-blind and', '52 weeks open-label) as an IV bolus into the venous line of the dialysis circuit at the end', 'of each dialysis session and may be given either during or after rinse back of the dialysis', 'circuit. If a patient receives additional dialysis during a given week for any reason, an', 'additional dose of CR845 or placebo will be administered following dialysis. A maximum', 'of 4 doses per week is allowed. No additional doses will be given for patients receiving', 'an additional unscheduled ultrafiltration treatment.', 'Following the IV push of study drug, the venous line must be flushed with at least 10 mL', 'of normal saline.', ""The patient's prescription dry body weight (ie, the target post-dialysis weight, as"", ""determined by the patient's nephrologist or dialysis unit during screening) will be used to"", 'calculate the dose of the study drug to be administered throughout the Double-blind', 'Treatment Period.', 'During the Open-label Treatment Period, the volume of CR845 to be administered will be', ""based on patient's prescription target dry body weight recorded on Day 1 of the"", 'Open-label Treatment Period, and adjusted if prescription dry body weight changes by', '10% or more from dry body weight being used for calculation of CR845 dose.', '6.4.2', 'Identity of Investigational Product(s)', '6.4.2.1', 'Formulation of Study Drug', 'Study drug will be supplied by the Sponsor as a solution in 2-mL glass vials containing a', 'minimum extractable volume of 1.3 mL of CR845 at a concentration of 0.05 mg/mL in', '0.04 M isotonic acetate buffer, pH 4.5. The composition of the CR845 solution contains', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 38 of 95']"
36,page_37,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 37 of 92', 'CR845-CLIN3102', 'CR845 (free base), acetic acid, sodium acetate trihydrate, sodium chloride, hydrochloric', 'acid, and water for injection.', 'Matching placebo (0.04M isotonic acetate buffer, pH 4.5) will be provided in 2-mL glass', 'vials containing a minimum extractable volume of 1.3 mL. The composition of the', 'placebo buffer solution is acetic acid, sodium acetate trihydrate, sodium chloride,', 'hydrochloric acid, and water for injection. The placebo buffer is identical to the buffer', 'solution used in the CR845 solution and has identical appearance as the solution', 'containing the active ingredient. The placebo buffer solution will be packaged, stored,', 'and shipped identically to the CR845 solution.', '6.4.2.2', 'Packaging, Labeling, and Storage Stability of Study Drug', 'Study drug will be shipped at 15C to 30C. Temperature will be monitored during', 'shipment and verified and recorded in the pharmacy log by pharmacist upon arrival at the', 'site. The vials must be stored at temperature ranging from 15C to 30C upon receipt and', 'temperature will be monitored accordingly.', 'For the Double-blind Treatment Period vials will be packaged (blinded) in boxed kits (also', 'blinded) containing 40 vials per box (4 extra vials for backup). Kits will be labeled with', 'patient ID number and kit number. A single box of vials will be assigned to a patient.', 'For the Open-label Treatment Period, vials will be packaged in boxed kits containing', '12 vials per box. Kits will be labeled with patient ID number and kit number. A single', 'box of vials will be assigned to a patient.', 'Labeling of the vials will include, but is not limited to, the following:', 'Study protocol number (CR845-CLIN3102)', 'Blinded name of study drug (CR845 0.5 mcg/kg or placebo IV solution) for the', 'Double-blind Treatment Period or name and concentration of study drug (CR845', '0.5 mcg/kg) for the Open-label Treatment Period', 'Batch or lot number (open-label only)', 'Temperature storage instructions (store at 15C to 30C)', 'Extractable volume: at least 1.3 mL', 'Name and location of Sponsor', 'Administer according to protocol', 'For Clinical Trial Use Only', 'The label on each kit will be the same as the label on an individual vial, and in addition,', 'will provide the number of vials contained per box (12 or 40). It will also include', '""Caution: New Drug- Limited by Federal (or United States) Law to Investigational Use.""', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 39 of 95']"
37,page_38,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 38 of 92', 'CR845-CLIN3102', '6.4.2.3', 'Individual Dose Labeling', 'One syringe will be prepared for each patient on each dosing day. Patients weighing', '>135.0 kg require modified preparation of CR845. Syringes and syringe labels will be', 'provided. Refer to the ISF for details.', '6.4.3', 'Drug Accountability', 'All supplies will be maintained under adequate security by the pharmacist or approved', 'staff at the investigational site. At the end of each injection, the used vials will be stored', 'until the study monitor performs accountability. Details of study drug accountability and', 'return are provided in the ISF.', 'The Sponsor (or delegated person) will be permitted, at intervals and upon request during', 'the study, to check the supplies, storage and dispensing procedures, and records.', '6.4.4', 'Method of Assigning Patients to Treatment Groups', 'Before the start of the study, computer-generated randomization schedules will be', 'prepared. Randomization will be performed using an interactive voice or web response', 'system (IVRS/IWRS). Patients will be randomized in a 1:1 ratio to receive either CR845', '0.5 mcg/kg IV or matching placebo IV during the Double-blind Treatment Period.', 'Patients will be stratified into 2 strata according to their use or non-use of concomitant', 'medications to treat their itch during the pre-randomization week (Run-in Period) as well', 'as the presence or absence of specific medical conditions. These specific medical', 'conditions include:', 'History of fall or fracture (related to fall)', 'Confusional state or mental status change or altered mental status or disorientation', 'Gait disturbance or movement disorder', 'All eligible patients providing consent for participation in the Open-label Treatment', 'Period will receive CR845 at a dose of 0.5 mcg/kg starting on Day 1 of the Open-label', 'Treatment Period.', '6.4.5', 'Preparation of CR845', 'In the Double-blind Phase of the study, a single vial of study drug will be used for each', ""patient. Each patient's prescription dry body weight will not exceed 135.0 kg."", 'In the Open-label Extension Phase of the study, 1 vial of CR845 will be used for patients', 'with a prescription dry body weight <135.0 kg. For patients with a prescription dry body', 'weight >135.0 kg, 2 vials of CR845 will be used to ensure that the full volume of study', 'drug can be prepared. Further details will be provided in the ISF.', 'Information on the study drug preparation can be found in the Pharmacy Manual.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 40 of 95']"
38,page_39,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 39 of 92', 'CR845-CLIN3102', '6.4.6', 'Management of Missed Doses', 'If a patient misses a dialysis visit and the planned dose of CR845 for that visit, dosing', 'should resume at the next dialysis visit.', 'Contact the Medical Monitor if patient compliance or safety is of concern.', '6.4.7', 'Treatment Compliance', 'Patient compliance with study drug is documented as part of standard procedures at the', 'dialysis units where study drug is administered.', '6.4.8', 'Blinding', 'During the Double-blind Treatment Period, patients, Investigators, study staff, and the', 'Sponsor will be blinded to study drug assignment.', 'For medically urgent or emergent situations that necessitate knowledge of study drug', 'assignment for patient management, the blind may be broken via the IVRS/IWRS.', 'Whenever possible, the Medical Monitor should be contacted prior to breaking the blind.', 'The Sponsor and Medical Monitor will receive a report whenever a patient blind is', 'broken.', '6.4.9', 'Prior, Concomitant, and Prohibited Medications', '6.4.9.1', 'Prior and Concomitant Medications', 'Prior medications (including vitamins and herbal supplements) are defined as those that', 'the patient has taken any time during the 3 months prior to the first dose of study drug on', 'Day 1 of the Double-blind Treatment Period. Concomitant medications are medications', 'that are taken from after the start of the first dose of study drug on Day 1 of the', 'Double-blind Treatment Period through the end of the Open-label Treatment Period or', 'early termination (ie, End-of-Treatment/Early Termination Visit).', 'Erythropoiesis-stimulating agents and IV iron administered to the patient will be recorded', 'as per the schedule of events (Table 2 and Table 3).', 'Use of antipruritic medications during the study will be recorded on an ongoing basis,', 'starting at screening.', 'All prior and concomitant medications, including over-the-counter medications used by', 'patients during this study, are to be recorded in the appropriate page of the eCRF, as', 'applicable.', '6.4.9.2', 'Restricted and Prohibited Medications', 'During the Treatment Period for either the Double-blind Phase or Open-label Extension', 'Phase, the following medications will be restricted or prohibited (Table 1).', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 41 of 95']"
39,page_40,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 40 of 92', 'CR845-CLIN3102', 'Table 1.', 'Restricted and Prohibited Medications', 'Drug, Drug Class, or Treatment', 'Restrictions During the Treatment Period', 'Investigational drug (other than the study', 'Not allowed', 'drug)', 'Ultraviolet light-B treatments', 'Not allowed', 'Naloxone, naltrexone, or mixed', 'Not allowed from the start of dosing of the', 'agonist-antagonists (eg, buprenorphine and', 'Double-blind Treatment Period to the end of', 'nalbuphine)', 'the Open-label Treatment Period, unless', 'needed to treat an adverse event or emergent', 'medical condition acutely.', 'Antihistamines (oral, IV, or topical)', 'Changes to current prescription should be', 'avoided from screening to the end of the', 'Corticosteroids (oral, IV, or topical)', 'Double-blind Treatment Period unless for the', 'treatments', 'acute treatment of an adverse event or', 'Opioids', 'emergent medical condition (in this case,', 'notify the study medical monitor and, as', 'Gabapentin, pregabalin', 'appropriate, report adverse events).', 'No new medication to treat itch should be', 'initiated.', 'All new concomitant medications or change of frequency and doses of a concomitant', 'medication will be recorded.', '6.5', 'Study Assessments and Procedures', '6.5.1', 'Schedule of Events for the Double-blind Phase', 'Study procedures for the Double-blind Treatment Period are summarized in Table 2.', 'An ICF will need to be signed prior to initiation of the Screening Visit and any procedures', 'that follow.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 42 of 95']"
40,page_41,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 41 of 92', 'CR845-CLIN3102', 'Table 2.', 'Schedule of Events: Double-blind Phase', 'Study Procedures', 'Double-blind End of', 'Screening', 'Run-in', 'Treatmentb/', 'Discontinuation', 'Visit9', 'Period', 'Double-blind Treatment Perioda', 'Early Termination', 'Period', 'Day -28 to', 'Day -7 to', 'Day -7', 'Day 1', 'Week 1', 'Week 2 to 12', 'Week 13', 'DP Days 2b-14', 'Visit Days', 'M/Tu', 'W/Th', 'F/Sa', 'M/Tu', 'W/Th', 'F/Sa', '-28 to -7', '-7 to 1', '1', '3', '5', '8', '10', '12', '85', '85 to 98', '15', '17', '19', '22', '24', '26', '29m', '31', '33', '36', '38', '40', '43', '45', '47', '50', '52', '54', '57 m', '59', '61', '64', '66', '68', '71th', '73', '75', '78', '80', '82', 'Administrative procedures', 'Informed consent', 'X', 'Inclusion/exclusion criteria', 'X', 'Medical history/Prior Medications (including', 'X', 'Xc', 'antipruritic medications)/Demographics', 'Randomization', 'Safety and efficacy evaluations', 'Physical examination', 'X', 'Prescription dry body weight', 'X', 'Pre-dialysis 12-lead electrocardiogramd', 'xd', 'xd', 'Pre-dialysis vital signs', 'X', 'Xe', 'Xe', 'Xe', 'xt', 'Hematology, serum chemistry (pre-dialysis)8', 'X', 'x', 'X', 'Serum pregnancy (females of childbearing', 'X', 'X', 'potential only)', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 43 of 95']"
41,page_42,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 42 of 92', 'CR845-CLIN3102', 'Table 2.', 'Schedule of Events: Double-blind Phase (Continued)', 'Study Procedures', 'Double-blind End of', 'Screening', 'Run-in', 'Treatmentb/', 'Discontinuation', 'Visit9', 'Period9', 'Double-blind Treatment Period', 'Early Termination', 'Period', 'Day -28 to', 'Day -7 to', 'First Day of', 'Day -7', 'Day 1', 'Week 1', 'Week 2 to 12', 'Week 13', 'DP Days 2b -14', 'Visit Days', 'M/Tu', 'W/Th', 'F/Sa', 'M/Tu', 'W/Th', 'F/Sa', '-28 to -7', '-7 to 1', '1', '3', '5', '8', '10', '12', '85', '85 to 98', '15', '17', '19', '22', '24', '26', '29""', '31', '33', '36', '38', '40', '43', '45', '47', '50', '52', '54', '57th', '59', '61', '64', '66', '68', '71th', '73', '75', '78', '80', '82', 'Safety and efficacy evaluations', 'Patient training on PRO worksheets', 'Xhij', 'X', 'Worst Itching Intensity NRS (daily)k', 'x', 'Record on an ongoing basis', 'X', 'Skindex-10 Scale, 5-D Itch Scalem', 'Xm', 'Xm', 'Patient Global Impression of Change', 'X', 'Patient Health Assessment (ShOWS) and', 'Observer Health Assessment (OOWS)', 'XX', 'XX', 'worksheets', 'Record dose of ESA and IV iron', 'Record on an ongoing basis', 'X', 'Record number of missed dialysis visits and', 'Record on an ongoing basis', 'reason(s)', 'IV administration of study drug', 'Record on an ongoing basis', 'Inflammatory biomarker samples', 'X', 'X', 'Adverse event monitoring', 'X', 'X', 'Record on an ongoing basis', 'X', 'X', 'Concomitant medications (including antipruritic', 'medications)', 'Record on an ongoing basis', 'X', 'X', 'Structured Safety Evaluation', 'X', 'X', 'X', 'DP = Discontinuation Period; ESA = erythropoiesis-stimulating agent; F = Friday, IV = intravenous; M = Monday; NRS = numerical rating scale; OOWS = Objective Opiate Withdrawal Scale;', 'PRO = patient-reported outcome; Sa = Saturday, ShOWS = Short Opiate Withdrawal Scale; Th = Thursday, Tu = Tuesday, W = Wednesday', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 44 of 95']"
42,page_43,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 43 of 92', 'CR845-CLIN3102', 'a.', ""Each visit during the Double-blind Treatment Period will coincide with the patient's normal dialysis treatments."", 'b. The End-of-Treatment Visit in the Double-blind Phase will be the first dialysis visit following the last dose of study drug (ie, first dialysis on Week 13 [Day 85]), which also corresponds to Day 1', 'of the Discontinuation Period (DP Day 1).', 'c.', 'Medical history will be updated on Day 1 with any changes since the Screening Visit, and inclusion/exclusion criteria will be confirmed prior to randomization. Antipruritic medication will be', 'updated at each dialysis visit during the Run-in Period.', 'd.', 'Electrocardiogram must be performed prior to the start of dialysis at screening, Day 85 (End of Treatment), or at Early Termination visit.', 'e.', 'Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded on Days 1, 15, 29, 43, 57, 71 and 85 (End of Treatment), or at Early Termination visit only', 'when the patient is in a sitting or semi-recumbent position. Heart rate will be measured at each dialysis; if heart rate is clinically significant and outside the prespecified visits per Schedule of', 'Events, the heart rate will be recorded on the relevant CRF page.', 'f.', 'Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded at each dialysis visit during the Discontinuation Period. Heart rate will be measured at each', 'dialysis.', 'g.', 'Blood samples for clinical laboratory evaluation will be taken at screening, and on Days 1 and 85 (End of Treatment), or at Early Termination', 'visit', 'only.', 'h.', 'Training on Worst Itching Intensity NRS will be conducted on the first day of the Run-in Period (Day -7).', 'i.', 'Training on ShOWS on Day -7 and first day of Week 13.', 'j.', 'Training on Skindex-10 Scale and 5-D Itch Scale may be performed at any time during the week prior to randomization or on Day 1 of the Double-blind Treatment Period', 'k.', 'Patients will be requested to complete their Worst Itching Intensity NRS worksheets each day at a similar time (either at home on non-dialysis days around the normal start time of their dialysis or', 'in the dialysis unit). On dialysis days, the worksheets will be completed prior to or during dialysis, but must be completed prior to dosing.', 'l. During the Discontinuation Period, Worst Itching Intensity NRS worksheets will be completed on dialysis days only.', 'm.', '5-D Itch Scale and Skindex-10 Scale completed on Day 1 and the first visit of Weeks 5, 9 and 11 (on Days 29, 57 and 71) and Week 13 (Day 85). 5-D Itch scale will preferably be completed first.', 'If the first visit of the week is missed, the patient may complete the worksheets at their next visit for the same week. The worksheets will be completed prior to or during dialysis (preferably within', '1 hour of the dialysis), but must be completed prior to dosing.', 'n.', 'ShOWS worksheets will be completed daily through the entire Discontinuation Period starting on Day 85. The OOWS worksheets will be completed at each dialysis visit during the', 'Discontinuation Period starting on Day 85. On the day of a dialysis visit, the OOWS and the ShOWS will be completed during the first hour (+1-hour window allowed) of dialysis so that dialysis-', 'associated patient fatigue and other potential side effects related to the dialysis procedure should minimally interfere with the', 'completion', 'of', 'the', 'scales.', 'o.', 'Biomarker samples must be collected prior to the start of dialysis on Day 1 and Day 85.', 'p', 'Concomitant medications including antipruritic medication will be updated at each dialysis visit during the Double-blind Treatment Period, and until the end of the Discontinuation Period.', 'q.', 'Sites have the option to conduct the Screening Visit during the Run-in Period at the discretion of the Investigator', 'r.', 'A list of specific signs/symptoms will be verified with the patient by qualified site staff, preferably to be completed on Wednesday/Thursday each week during the Run-in Period, the Double-blind', 'Treatment Period and the Discontinuation Period. Not to be completed on Monday/Tuesday.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 45 of 95']"
43,page_44,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 44 of 92', 'CR845-CLIN3102', '6.5.2', 'Schedule of Events for the Open-label Extension Phase', 'Study procedures for the Open-label Extension Phase are summarized in Table 3.', 'The safety assessment visit may occur on any chosen dialysis day of a scheduled week as', 'long as all assessments are completed during that visit. Patients who miss one of the', 'scheduled study visit weeks (eg, Week 4 of open-label treatment) may complete this visit', 'at their next dialysis treatment if conducted within 2 weeks of the scheduled visit.', 'Unscheduled visits may be necessary for outstanding, unresolved adverse events', '(eg, additional safety laboratory or clinical evaluations). At minimum, for any', 'unscheduled visit, the reason for the visit will be recorded, the adverse events reported, as', 'well as changes to concomitant medications, as applicable. Additional testing', '(eg, laboratory tests, vital signs, ECGs) will be performed as clinically indicated.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 46 of 95']"
44,page_45,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 45 of 92', 'CR845-CLIN3102', 'Table 3.', 'Schedule of Events: Open-label Extension Phase', 'Open-label Treatment Perioda Up to 52 Weeks of Dosing', 'Follow-Up', 'First Dialysis of', 'Week 53b', '7 - 10 days after End of', 'End of Treatment', 'Treatment/Early', 'Termination', 'Study Procedures', 'Day 1c', 'Week 4', 'Week 8', 'Week 12a', 'Week 24', 'Week 36a', '/Early Termination', 'Administrative procedures', 'Inclusion/exclusion criteria', 'Safety and other evaluations', 'Physical examination', 'Record prescription dry body weighte', 'Record every 12 weekse', 'Pre-dialysis 12-lead electrocardiogram', 'X', 'Pre-dialysis vital signs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Hematology, serum chemistry', 'X', 'X', 'X', '(pre-dialysis)', 'Serum pregnancy test for women of', 'X', 'X', 'childbearing potential only', 'Record dose of ESA and IV iron', 'X', 'Record on ongoing basish', 'Record number of missed dialysis visits', 'Record on an ongoing basis', 'and reason(s), as applicable', 'IV administration of study drug', 'X', 'Dose after each dialysis up to Week 52 included', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 47 of 95']"
45,page_46,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 46 of 92', 'CR845-CLIN3102', 'Table 3.', 'Schedule of Events: Open-label Extension Phase', '(Continued)', 'Open-label Treatment Perioda Up to 52 Weeks of Dosing', 'Follow-Up', 'First Dialysis of Week', '53b', '7 - 10 days after End of', 'Treatment/Early', 'End of Treatment /Early', 'Termination', 'Study Procedures', 'Day 1c', 'Week 4', 'Week 8', 'Week 12a', 'Week 24', 'Week 36a', 'Termination', 'Safety and other evaluations', '5-D itch scale', 'X', 'X', 'X', 'X', 'X', 'X', 'Inflammatory biomarker samples*', 'X', 'X', 'Adverse event monitoring', 'Record on an ongoing basis', 'Concomitant medications (including', 'antipruritic medications)', 'Record on an ongoing basis', 'ESA = erythropoiesis-stimulating agent; IV = intravenous', 'a.', ""Each visit during the Open-label Treatment Period will coincide with the patient's normal dialysis treatments. The study visit may occur on any chosen dialysis day of a"", 'scheduled week as long as all assessments are completed during that visit. Patients who miss one of the scheduled study visit weeks (eg, Week 4) may complete the visit', 'procedures for this visit at their next dialysis treatment as long as it is within 2 weeks of the originally scheduled visit date.', 'b.', 'The End-of-Treatment Visit will be the first dialysis visit following the last dose of study drug (ie, first dialysis on Week 53).', 'c.', 'Day', '1 of the Open-label Treatment Period corresponds to the week after the Discontinuation Period of the Double-blind Phase (+1 week window allowed).', 'd. Prior to dosing on Day 1 of the Open-label Treatment Period, the inclusion/exclusion criteria will be confirmed.', 'e.', 'The prescription dry body weight will be captured from the dialysis prescription and will be recorded on Day 1 and every 12 weeks during the Open-label Treatment Period', '(during Weeks 12, 24, 36, and 48). If there is a >10% change in prescription dry body weight, then the CR845 dose will be adjusted. The date of prescription dry body', 'weight change will also be recorded.', 'f.', 'Electrocardiogram must be performed prior to the start of dialysis.', 'g.', 'Vital signs, including body temperature, heart rate, and blood pressure, will be obtained at the specified visits while the patient is in a sitting or semi-recumbent position prior', 'to the start of dialysis. Heart rate will be measured at each dialysis; if the heart rate is clinically significant and outside the prespecified visits per Schedule of Events the heart', 'rate will be recorded on the relevant CRF page.', 'h.', 'Doses of ESA and IV iron administered will be recorded for the 4-week period ending on Weeks 4 (Day 1 to Week 4), 12 (Week 9 to 12), 24 (Week 21 to 24), 36 (Week 33 to', '36), and 52 (Week 49 to 52) or for the 4 weeks before Early Termination Visit. Preferably record at the end of the specified week, which corresponds to the beginning of the', 'following calendar week (ie, end of Week 4 is the Monday/Tuesday of Week 5)', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 48 of 95']"
46,page_47,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 47 of 92', 'CR845-CLIN3102', 'i.', 'Administered after each dialysis as an IV bolus.', 'j.', 'To be completed in the dialysis unit at any time priortoor during dialysis,but must be done prior to dosing. Preferably at the end of the specified week, which corresponds to', 'the beginning of the following calendar week (ie, end of Week 4 is the Monday/Tuesday of Week 5).', 'k.', 'Biomarker samples must be collected prior to the start of dialysis.', '1.', 'Adverse events and concomitant medications will be recorded starting on Day 1 of the Open-label Treatment Period.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 49 of 95']"
47,page_48,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 48 of 92', 'CR845-CLIN3102', '6.5.3', 'Efficacy Assessments', 'The effect of CR845 on itch will be measured by means of the following PRO measures:', 'Worst Itching Intensity NRS score', 'Skindex-10 Scale', '5-D Itch Scale', 'Patient Global Impression of Change', 'Patients will be trained on completion of the Worst Itching Intensity NRS scale at the', 'first visit of the Run-in Period, and will be trained on the other itch-related PRO measures', 'at any time during the Run-in Period or on Day 1 of the Double-blind Treatment Period.', 'All questionnaires must be completed in strict adherence to the Training Manual for', 'Patient Reported and Observer-reported Assessments.', '6.5.3.1', 'Worst Itching Intensity Numerical Rating Scale', 'Intensity of itch will be measured using an NRS scale (Appendix 2, Section 14.2) on a', 'worksheet on which patients will be asked to indicate the intensity of the worst itching', 'they experienced over the past 24 hours by marking one of 11 numbers, from 0 to 10, that', 'best describes it, where ""0"" is labeled with the anchor phrase ""no itching"" and ""10"" is', 'labeled ""worst itching imaginable.\' Patients will be provided with these worksheets to', 'record their 24-hour worst itching assessment scores, both at the clinic on dialysis days', 'and at home on nondialysis days.', 'The Worst Itching Intensity NRS has been widely utilized for evaluation of chronic itch,', 'including uremic pruritus [Kumagai 2010; Pisoni 2006; Mathur 2010; Stnder 2013].', '6.5.3.2', 'Skindex-10 Scale', 'Developed specifically for uremic pruritus, the Skindex-1 Scale (Appendix 3,', 'Section 14.3) is an instrument for measurement of quality-of-life that correlates with itch', 'intensity [Mathur 2010]. Patients are asked to mark 1 of 7 boxes numbered from 0', '(labeled with the anchor phrase ""never bothered"") to 6 (labeled as ""always bothered"") for', 'each of the 10 questions describing how often they have been bothered by their itch and', 'its impact over the past week. The total score is the sum of the numeric value of each', 'answered question. The total score is subdivided into 3 domain scores, which are sums', 'of the scores of the following questions: disease domain (questions 1 to 3),', 'mood/emotional distress domain (questions 4 to 6), and social functioning domain', '(questions 7 to 10).', '6.5.3.3', '5-D Itch Scale', 'The 5-D Itch Scale was developed as a brief, multidimensional questionnaire designed to', 'be useful as an outcome measure in clinical studies. The 5 dimensions of itch assessed', 'are degree, duration, direction, disability, and distribution (Appendix 4, Section 14.4).', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 50 of 95']"
48,page_49,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 49 of 92', 'CR845-CLIN3102', 'Patients are asked to mark boxes that best describe the impact of their itch over the past', '2 weeks. The scale has been validated in patients with chronic pruritus, including', 'hemodialysis patients and has been shown to be sensitive to changes in pruritus over time', '[Elman 2010].', '6.5.3.4', 'Patient Global Impression of Change', 'The Patient Global Impression of Change is a global PRO measure that assesses the', 'change in itch (no change, improvement or worsening) overall relative to the start of the', 'study [Dworkin 2005]. The scale has only 1 item, and the patient is asked to mark the', 'category that best describes the change in itch ranging from ""Very Much Improved"" to', '""Very Much Worse"" (Appendix 5, Section 14.5).', '6.5.4', 'Safety Assessments', 'During both the Double-blind and Open-label Phases, the safety assessments for each', 'patient are the following:', 'Severity, seriousness, and relationship of adverse events to study drug', 'Structured Safety Evaluation by site staff', 'Physical examination', 'Vital signs', '12-lead ECGs', 'Clinical laboratory tests', '6.5.4.1', 'Adverse Events', 'Definition of Adverse Events', 'An adverse event is any untoward medical occurrence in a patient or clinical', 'investigational patient administered a medicinal product and which does not necessarily', 'have to have a causal relationship with this treatment. An adverse event can therefore be', 'any unfavorable and unintended sign (including an abnormal laboratory finding, for', 'example), symptom, or disease temporally associated with the use of a medicinal product,', 'whether or not considered related to the medicinal product.', 'In this study, adverse events will be captured from the time a patient signs the ICF to the', 'Follow-up Visit and include the following:', 'Any new sign, symptom, or disease;', 'Any new clinically significant or symptomatic laboratory/diagnostic test', 'abnormality;', 'Any clinically significant worsening of laboratory/diagnostic test abnormality;', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 51 of 95']"
49,page_50,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 50 of 92', 'CR845-CLIN3102', 'Any worsening (ie, clinically significant change in frequency, nature, and/or', 'intensity) of a pre-existing condition.', 'A pre-existing condition is a condition that is present prior to signing the ICF for the', 'study. Pre-existing conditions, such as illnesses, symptoms, reactions, progression of', 'disease states, and other comorbidities, as well as laboratory/diagnostic test', ""abnormalities, will be documented in the patient's record as medical history."", 'Signs and symptoms will be reported individually as adverse events (non-serious), unless', 'a medical diagnosis was provided. Medical diagnosis, whenever provided, will be', 'reported rather than individual signs and symptoms.', 'Any adverse event that satisfies any of the seriousness criteria described below will be', 'reported as an SAE using the SAE Report Form, in addition to documenting in the eCRF.', 'Serious adverse events that occurred up to 30 days after the last dose of study drug need', 'to be documented on an SAE Report Form if they are deemed by the Investigator to be', '""Related"" to study drug.', 'Adverse Event Severity Assessment', 'The Investigator will assess the severity (ie, intensity) of each adverse event (serious and', 'non-serious) reported during the study based on his/her clinical judgment. The severity', 'of each adverse event will be assigned to one of the following categories:', 'Mild:', 'Transient, requires no special treatment, is easily tolerated by the', 'patient, causes minimal discomfort, and does not interfere with the', ""patient's daily activities"", 'Moderate:', 'Introduces a level of inconvenience or concern to the patient that may', 'interfere with daily activities, but usually is ameliorated by simple', 'therapeutic measures', 'Severe:', ""Interrupts a patient's usual daily activity and requires systemic drug"", 'therapy or other treatment', 'Definition of Serious Adverse Events', 'An SAE is any untoward medical occurrence that:', 'Results in death;', 'Is life-threatening;', 'NOTE: The term ""life-threatening"" in the definition of ""serious"" refers to an', 'event in which the patient was at risk of death at the time of the event; it does', 'not refer to an event which hypothetically might have caused death if it were', 'more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization;', 'Results in persistent or significant disability/incapacity; or', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 52 of 95']"
50,page_51,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 51 of 92', 'CR845-CLIN3102', 'Is a congenital anomaly/birth defect.', 'Medical and scientific judgment should be exercised in deciding whether expedited', 'reporting is appropriate in other situations, such as important medical events that may not', 'be immediately life-threatening or result in death or hospitalization, but may jeopardize', 'the patient or may require intervention to prevent one of the other outcomes listed in the', 'definition above. These are usually considered serious.', 'Severe versus Serious Adverse Event', 'The term ""severe"" is used to describe the intensity (severity) of a specific event (as in', 'mild, moderate, or severe myocardial infarction); the event itself, however, may be of', 'relatively minor medical significance (such as severe headache). An adverse event as', 'well as an SAE must be assessed for severity. An adverse event that is assessed as severe', 'should not be confused with an SAE. ""Severity"" is not the same as ""Serious,"" which is', 'based on patient outcome or reaction criteria usually associated with events that pose a', ""threat to a patient's life or functioning. Seriousness (not severity) serves as a guide for"", 'defining regulatory reporting obligations.', 'Adverse Event Causality or Relatedness to the Study Drug', 'Every effort should be made by the Investigator to explain each adverse event and assess', 'its relationship, if any, to study drug. The Investigator should consider many factors,', 'including, but not limited to, temporal association of the event and date/time of study', 'drug, duration of study drug, medical/biologic plausibility, pharmacology and adverse', 'event profile of study drug, medical history (past medical history, underlying disease,', 'comorbidities, intercurrent illness), concomitant medications, medical judgment,', 'dechallenge, rechallenge, drug interaction, other plausible causes, etc., to determine the', 'causality assessment of an event.', 'The Investigator as well as the Sponsor will determine adverse event/SAE causality as', '""Related\' or ""Not Related\' to study drug. Although there is no international consensus on', 'how to define ""Related\' and ""Not Related, in general, an event is considered ""Related\' if', 'there is reasonable possibility that the event is related to study drug than to any other', 'possible cause(s). Conversely, an event is considered ""Not Related\' if there is reasonable', 'possibility that the event is related to other factors than the study drug.', 'Adverse Event Documentation and Follow-up', 'All adverse events, including observed, elicited, or volunteered problems, complaints, or', ""symptoms are to be recorded on the adverse event page in the patient's eCRF from the"", 'time the patient signs the ICF and until the Follow-up Visit/early termination, whether or', 'not judged by the Investigator to be related to study drug. The need to capture this', 'information is not dependent upon whether adverse events are related to study drug.', 'Serious adverse events that occurred up to 30 days after the last dose of study drug need', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 53 of 95']"
51,page_52,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 52 of 92', 'CR845-CLIN3102', 'to be documented on an SAE Report Form if they are deemed by the Investigator to be', '""Related"" to study drug.', 'Each adverse event is to be documented with a verbatim/reported term, start and stop date', 'and time, severity, causal relationship to study drug, action taken with study drug, and', 'outcome (resolved, resolved with sequelae, resolving, fatal, unknown). The Investigator', 'must review new adverse events and the outcome of ongoing adverse events frequently', 'throughout the study.', ""In addition to recording all adverse events (serious and non-serious) in the patient's"", 'eCRF, all SAEs must also be documented on the SAE Report Form for the study.', 'The Investigator will follow all adverse events until they resolve, the Investigator', ""assesses them to be stable, or the patient's participation in the study ends, whichever"", 'comes first. In addition, the Investigator will follow all adverse events assessed as related', ""to study drug that are ongoing at the time of the patient's last visit, until they resolve or"", ""the Investigator assesses them as stable, even if the patient's participation in the study has"", ""ended. Resolution of such events is to be documented in the patient's record as"", 'appropriate.', 'It is anticipated that some patients may undergo procedures and/or experience events that', 'are common in the study population under investigation, independent of study therapy.', 'Preplanned procedures and procedures (eg, kidney transplant, catheter replacement) or', ""events that are independent of study therapy, according to the Investigator's assessment,"", 'will be documented as specified in the Safety Management Plan. Common procedures or', 'events (new or ongoing) for which the Investigator cannot rule out the role of study drug', 'in their evolution, either because their nature or severity is not consistent with that', 'generally seen in the study population or because of other valid medical/scientific', 'rationale, will be recorded and reported as adverse events with all the attributes required', 'for appropriate medical assessment.', 'Serious Adverse Event Notification, Documentation, and Reporting', 'The Investigator will report an SAE within 24 hours of becoming aware of the event. An', 'SAE Report Form will be completed regardless of relationship to the study drug. The', 'initial report will not be delayed in order to obtain additional information. Any additional', 'information will be reported as a follow-up to the initial report within 24 hours of', 'collection.', 'Details for reporting and follow-up of SAEs are provided in the ISF.', 'In the event of any SAE (other than death) occurring after the last dose of study drug and', 'prior to the Follow-up Visit, the patient will be instructed to contact the Investigator or', 'designee immediately using the instructions provided on the ICF.', 'The Medical Monitor will review reported SAEs and may contact the Investigator', 'directly for further information.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 54 of 95']"
52,page_53,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 53 of 92', 'CR845-CLIN3102', 'The Sponsor will comply with the applicable local regulatory requirements related to', 'reporting of SAEs to the Food and Drug Administration (FDA), while the Investigator', 'and designated study personnel will comply with the applicable local regulatory', 'requirements related to reporting of SAEs to the IRB and Sponsor.', 'It is the responsibility of the Sponsor to send all regulatory reports to the FDA. Adverse', 'events that are serious, related to the study drug, and unexpected (per the', ""Investigator's Brochure) will be reported to the FDA as per Code of Federal Regulations"", '(CFR) 21 CFR 312.32 on Investigational New Drug (IND) safety reporting and as', 'specified in the Safety Management Plan.', ""For regulatory reporting purposes, the Sponsor can upgrade the Investigator's assessment"", '(eg, from not related to related); however, Cara Therapeutics cannot downgrade the', ""Investigator's assessment unless the Investigator determines that a re-assessment of"", 'causality is necessary. The Medical Monitor will review and comment on any upgrade', 'made to a report. If there is any doubt concerning the relationship between study drug', 'and the event, then the relationship should be considered to be related to study drug.', 'As applicable, the Sponsor will also notify other participating Investigator(s) of all IND', 'Safety Reports to ensure prompt notification of significant new adverse events or risks', 'with respect to study drug. This notification will occur as soon as possible and in', 'compliance with country-specific regulations.', 'Refer to the Safety Management Plan for further details about SAE reporting and', 'processing. The Medical Monitor should be contacted by study sites requiring additional', 'clarification on an SAE.', '6.5.4.2', 'Structured Safety Evaluation', 'A weekly Structured Safety Evaluation will also be used during the Double-Blind Phase', 'to proactively identify and monitor adverse events of special interest.', 'The Structured Safety Evaluation will be performed once during the Run-in Period and', 'weekly (preferably on Wednesday/Thursday during the Double-blind Treatment Period', 'and Discontinuation Period. The Structured Safety Evaluation will be performed by', 'qualified study staff using a list of specific signs/symptoms, including mental status', 'change, falls and gait disturbance.', '6.5.4.3', 'Physical Examination', 'Physical examinations will include an examination of the heart, lungs, abdomen,', 'extremities, and neurological and vascular systems. Clinically significant abnormalities', 'or worsening findings observed after the first dose of study drug will be reported as', 'treatment-emergent adverse events (TEAEs).', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 55 of 95']"
53,page_54,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 54 of 92', 'CR845-CLIN3102', '6.5.4.4', 'Vital Signs', 'Vital signs include sitting or semi-recumbent body temperature, heart rate, and blood', 'pressure and will be measured prior to start of dialysis.', 'Measurements will be repeated if a value is out of the reference range due to a technical', 'issue, considered abnormal for the patient, or for other medical concerns. Only the', 'repeated measurement will be recorded.', 'In the event of a clinically significant change in blood pressure and/or heart rate, the', 'Investigator and dialysis staff will evaluate and manage the patient per standard dialysis', ""unit practices with knowledge of the patient's typical blood pressure and heart rate"", 'excursions.', 'Heart rate will be collected at each dialysis; if clinically significant and outside the', 'prespecified visits per schedule of events, the heart rate will be recorded on the relevant', 'CRF page.', '6.5.4.5', 'Electrocardiogram', 'The 12-lead ECGs will be obtained prior to the start of dialysis and will be read locally', 'by the Investigator or qualified designee. Electrocardiograms read by a qualified', 'designee must be endorsed by the Investigator. Clinically significant abnormalities or', 'worsening findings observed after the first dose of study drug will be reported as', 'treatment-emergent adverse events (TEAEs).', '6.5.4.6', 'Clinical Laboratory Tests', 'Blood samples for clinical laboratory tests including hematology, serum chemistry, and', 'serum pregnancy will be taken prior to dialysis and will be analyzed by a central', 'laboratory. Processing and shipment of central laboratory samples will be described in', 'the Laboratory Manual, along with the final list of laboratory tests.', '6.5.4.7', 'Contraception and Pregnancy', 'All females of childbearing potential will have blood samples taken at Screening for', 'serum pregnancy testing. Females are considered to be of childbearing potential unless', 'they are:', 'Surgically sterile (ie, tubal ligation, bilateral oophorectomy, and/or', 'hysterectomy); or', 'Over 55 years of age and have not had a menstrual period in at least 1 year', 'Once they have consented to participate in the study, all women of childbearing potential', 'will be counseled on the importance of avoiding pregnancy and on the need to practice', 'adequate birth control for the duration of the study, from screening until 7 days after the', 'last dose of study drug.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 56 of 95']"
54,page_55,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 55 of 92', 'CR845-CLIN3102', 'Medically acceptable methods of birth control are methods with a failure rate of <1% per', 'year, and include hormonal contraceptives for at least 1 cycle of treatment before study', 'enrollment, an intrauterine device, and double-barrier method (eg, male or female', 'condom, diaphragm).', 'Per inclusion criteria, male patients will agree not to donate sperm after the first dose of', 'study drug until 7 days after the last dose of study drug, and will agree to use a condom', 'with spermicide or abstain from heterosexual intercourse during the study until 7 days', 'after the last dose of study drug. No restrictions are required for a vasectomized male,', 'provided his vasectomy was performed >4 months prior to dosing.', 'Women will be counseled to contact the Investigator or his/her staff immediately if', 'pregnancy is suspected. Males will be instructed to report to the Investigator if their', 'partner becomes pregnant during the study.', 'If a patient becomes pregnant during the Double-blind or Open-label Treatment Periods', 'or within 7 days after the last dose of study drug, the Investigator will immediately', 'discontinue the patient from the study and contact the Sponsor or designee. Diligent', 'efforts will be made to determine the outcome for all pregnancies in the clinical study.', 'Information on the status of the mother and the child will be forwarded to the Sponsor.', 'Generally, follow-up will occur within 6 to 8 weeks following the estimated delivery', 'date. Any premature termination of the pregnancy will be reported. Both maternal and', 'paternal exposure will be collected. For exposure involving the female partner of a male', 'patient, the necessary information must be collected from the patient while respecting the', 'confidentiality of the partner. A pregnancy report will be completed.', '6.5.5', 'Additional Assessments', 'The following additional assessments will be collected during the Double-blind and', 'Open-label Extension Phases:', 'Inflammatory biomarkers', 'Missed dialysis visits', 'ESAs and IV iron', '6.5.5.1', 'Inflammatory Biomarkers', 'Inflammatory biomarkers, such as interleukin (IL)-6, IL-8, and granulocyte', 'macrophage-colony stimulating factor will be measured, as defined in the statistical', 'analysis plan (SAP). A blood sample of sufficient volume to provide for replicate assays', 'of each biomarker will be collected prior to dialysis per the schedules of events.', 'Detailed instructions for biomarker sample collection and processing will be provided in', 'the laboratory manual.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 57 of 95']"
55,page_56,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 56 of 92', 'CR845-CLIN3102', '6.5.5.2', 'Missed Dialysis Visits', 'The number and reason(s) for missed dialysis will be recorded.', '6.5.5.3', 'ESAs and IV Iron', 'Use of ESA and iron will be recorded and reported on the appropriate eCRF page.', '6.5.5.4', 'Discontinuation Period Additional Assessments', 'Short Opiate Withdrawal Scale', 'The SOWS-Gossop (or ShOWS) is a self-administered scale for grading opioid', 'withdrawal symptoms over a 24-hour period. It was chosen because of its validation as', 'an opioid withdrawal measure [Gossop 1990; Bradley 1988; Vernon 2016] and frequent', 'use in clinical studies. This patient-rated scale consists of 10 items, scored from 0 (none)', 'to 3 (severe) (total score range 0-30). This scale is demonstrated to be a valid and', 'reliable indicator of the severity of the opiate withdrawal syndrome over a wide range of', 'common signs and symptoms. The higher the score, the greater the severity of associated', 'withdrawal.', 'The ShOWS will be presented as a paper worksheet to be filled by each patient at home', 'on nondialysis days and at the dialysis unit on dialysis days, at similar time of the day for', 'a given patient during the 2-week discontinuation period (during which no study drug', 'will be administered).', 'Objective Opiate Withdrawal Scale', 'The OOWS-Handelsman contains 13 physically observable signs, rated present (score of', '1) or absent (score of 0) (total score range 0-13), based on a timed period of 5 to', '10 minutes of observation of the patients by a rater [Handelsman 1987]. Higher total', 'scores will indicate more severe withdrawal signs. The rater will be a qualified staff', 'member who will be trained by the Sponsor. This scale is demonstrated to be a valid and', 'reliable indicator of the severity of the opiate withdrawal syndrome over a wide range of', 'common signs and symptoms.', 'The OOWS will be presented as a paper worksheet to be filled by a qualified staff', 'member at the dialysis unit on dialysis days, at similar time of the day for a given patient', 'during the 2-week discontinuation period (during which no study drug will be', 'administered).', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 58 of 95']"
56,page_57,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 57 of 92', 'CR845-CLIN3102', '7.0', 'Discussion and Justification of Study Design', '7.1', 'Discussion of Study Design and Choice of Control Groups', 'The double-blind part of the study was designed to evaluate the efficacy and safety of', 'IV CR845 in hemodialysis patients with moderate-to-severe pruritus. A randomized,', 'double-blind design was chosen to minimize bias. A 12-week duration of treatment was', 'selected to demonstrate durability of the efficacy observed in a prior 8-week treatment', 'study (ie, Study CR845-CLIN2101) and to further evaluate safety during a longer', 'exposure. The primary efficacy endpoint was determined using the Worst Itching', 'Intensity NRS scale, which measures itching intensity over 24 hours. This scale has been', 'validated for this patient population and is identical to the primary efficacy endpoint used', 'in the dose-ranging, Phase 2 study, CR845-CLIN2101. The Discontinuation Period of', 'the Double-blind Phase of the study has been designed to assess potential physical', 'dependence on CR845 in accordance with the FDA abuse liability guidance', '[Guidance for Industry January 2017].', 'The open-label part of the study was designed to evaluate the safety of CR845', '0.5 mcg/kg IV administered after each dialysis session (generally 3 times per week for up', 'to 52 weeks) in patients who completed the 12-week Double-blind Treatment Period of', 'this study. This design is commonly used in clinical development to obtain long-term', 'safety information. The duration of the study is in accordance with International Council', 'for Harmonisation (ICH) and FDA guidance [Guidance for Industry February 2016].', '7.2', 'Selection of Doses in the Study', 'The combined safety, pharmacokinetic, and efficacy data from CR845-CLIN2101', '(Part A) provided the basis for the selection of the dose and dose regimen of CR845 to be', 'used in this study. The lowest dose tested (0.5 mcg/kg IV) appeared to be well tolerated', 'and effective at reducing itch intensity over a period of 8 weeks.', '7.3', 'Appropriateness of Measurements', 'Standard clinical, laboratory, and statistical procedures and methodology will be utilized', 'in this study. The PRO assessments to be used in this study are appropriate.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 59 of 95']"
57,page_58,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 58 of 92', 'CR845-CLIN3102', '8.0', 'Statistical Methods', '8.1', 'General Considerations', 'This section describes the statistical analysis of efficacy and safety data collected during', 'the Double-blind Phase only. The analysis of safety and efficacy data collected during', 'the Open-label Phase will be included in the SAP.', 'The SAP will provide a detailed description for the handling of missing data, patient', 'eligibility criteria for the analysis, and statistical methodology. If differences occur', 'between analyses of double-blind data described in the SAP and the current protocol,', 'those found in the SAP will assume primacy. In addition, the SAP will provide details', 'for the analysis of data collected during the Open-label Phase, including the analysis of', 'safety data during exposure to CR845 across both the Double-blind and the Open-label', 'Phases.', 'Unless otherwise noted, continuous variables will be summarized using number of', 'non-missing observations, mean, standard deviation, median, minimum, and maximum;', 'categorical variables will be summarized using the frequency count and the percentage of', 'patients in each category. In addition to the descriptive summaries, pertinent data listings', 'will be provided.', 'All analyses will be performed using SAS version 9.2 or higher, unless otherwise', 'specified.', '8.2', 'Determination of Sample Size', 'The planned sample size for this study is 350 (175 per treatment group) male and female', 'hemodialysis patients with chronic moderate-to-severe pruritus (mean baseline 24-hour', 'Worst Itching Intensity NRS score >4), randomized at approximately 80 clinical sites.', 'The sample size may be increased to 500 patients (250 per treatment group) based on the', 'results of a planned unblinded interim assessment conducted when approximately 50% of', 'the planned 350 first patients have been randomized and have either completed the', '12-week Double-blind Treatment Period or have discontinued from double-blind', 'treatment early. The planned interim assessment will be conducted by an Independent', 'Data Monitoring Committee (IDMC). Details related to the sample size re-estimation are', 'included in Section 8.4.1.', 'The sample size calculation is based on results of a completed Phase 2 double-blind,', 'placebo-controlled study (CR845-CLIN2101) of CR845 in hemodialysis patients with', 'ESRD who had moderate-to-severe pruritus. In this study, 30% of patients randomized', 'to the placebo group reported >3-point improvement from baseline with respect to the', '24-hour Worst Itching Intensity NRS at the end of treatment (Week 8). The proportion of', 'patients who received CR845 and reported a similar improvement in itch scores ranged', 'from approximately 60% to 45% (ie, 30% to 15% difference from placebo), depending', 'on the dose of active study drug (0.5 mcg/kg, 1.0 mcg/kg, 1.5 mcg/kg).', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 60 of 95']"
58,page_59,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 59 of 92', 'CR845-CLIN3102', 'Given a sample size of 350 patients (175 per treatment group) and assuming a true', 'response rate of 30% for the placebo group and a true response rate of 50% for the', 'CR845 group (defining response as an improvement from baseline >3 points with respect', 'to the Worst Itching Intensity NRS at Week 12), a 2-sided continuity corrected', 'Chi-square will have 96% power to detect a treatment difference. The power of this test', 'statistic would be >84% for differences from placebo as low as 0.16 (Table 4).', 'Table 4.', 'Power as a Function of Effect Size (N = 175 per arm)', 'Placebo Response', '0.30', '0.30', '0.30', '0.30', 'CR845 Response', '0.50', '0.48', '0.46', '0.45', 'Odds Ratio', '2.333', '2.154', '1.988', '1.909', 'Power', '96%', '92%', '84%', '79%', 'a.', 'Power for a 2-sided Chi-square continuity-corrected test and a 5% Type 1 error.', 'Based on results of a planned interim assessment, the sample size may be increased up to', '500 patients (250 per treatment group). Given this maximum sample size, and assuming', 'a true response rate of 30% in the placebo group, a 2-sided continuity corrected', 'Chi-square would have approximately 90% power to detect a treatment difference when', 'the CR845 response rate is 45% (a 15% difference from placebo) (Table 5).', 'Table 5.', 'Sample Size as a Function of Odds Ratio (90% Power)', 'Placebo Response', '0.30', '0.30', '0.30', '0.30', '0.30', 'CR845 Response', '0.50', '0.48', '0.46', '0.45', '0.44', 'Odds Ratio', '2.333', '2.154', '1.988', '1.909', '1.833', 'Sample Sizea', '134', '164', '204', '230', '262', 'a.', 'Sample size for a 2-sided Chi-square continuity-corrected test and a 5% Type 1 error.', '8.3', 'Randomization', 'Before the start of the study, a computer-generated randomization schedule will be', 'prepared. Randomization will be performed using an IVRS/IWRS. Patients will be', 'randomized in a 1:1 ratio to receive either CR845 0.5 mcg/kg IV or matching placebo IV', 'during the Double-blind Treatment Period. Patients will be stratified according to their', 'use or non-use of concomitant medications to treat their itch during the week prior to', 'randomization (Run-in Period) as well as the presence or absence of specific medical', 'conditions. These medical conditions include:', 'History of fall or fracture (related to fall)', 'Confusional state or mental status change or altered mental status or', 'disorientation', 'Gait disturbance or movement disorder', 'All eligible patients who sign the ICF for participation in the Open-label Treatment', 'Period will receive CR845 at a dose of 0.5 mcg/kg starting on Day 1 of the Open-label', 'Extension Phase.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 61 of 95']"
59,page_60,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 60 of 92', 'CR845-CLIN3102', '8.4', 'Interim Analysis', '8.4.1', 'Sample Size Re-estimation', 'An unblinded interim analysis for sample size re-estimation will be conducted when', 'approximately 50% of the first 350 patients have been randomized and have either', 'completed the 12-week Double-blind Treatment Period or have discontinued from', 'double-blind treatment early. The planned interim assessment will be conducted by an', 'IDMC. An unblinded statistician who will not be part of the study team will provide', 'results of the interim analysis to the IDMC members. Members of the IDMC will not', 'participate in the DSMB and will not be members of the study team. During the interim', 'assessment, the study team will remain blinded to the data; however, the IDMC will', 'receive unblinded summary results to implement the decision rule for sample size', 're-estimation. The IDMC will only communicate the decision to either keep the original', 'sample size or to increase it; no other results will be provided to blinded staff. The', 'DSMB will be made aware of the decision, but not given the results that were the basis of', 'the decision.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 62 of 95']"
60,page_61,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 61 of 92', 'CR845-CLIN3102', '8.4.2', 'Safety Data Review', 'The operation of the DSMB will be governed by a charter that will describe the meeting', 'frequency, procedures, and requirements for reporting its observations to the Sponsor.', 'Safety data will be reviewed on an ongoing basis by the Sponsor and a DSMB. In order', 'to actively monitor patient safety, a prospective approach will be taken to collect and', 'analyze specific adverse events designated as adverse events of special interest.', '8.5', 'Analysis Populations', 'The Enrolled Population is defined as the group of patients who sign informed consent.', 'The ITT Population is defined as the group of patients who are randomized to a treatment', 'group.', 'The Double-blind Safety Population is defined as the group of randomized patients who', 'received at least 1 dose of double-blind study drug during the Double-blind Treatment', 'Period.', 'Following the intent-to-treat principle, patients in the ITT population will be analyzed', 'according to their randomized treatment, regardless of the actual treatment received.', 'Patients in the Double-blind Safety Population will be analyzed according to the actual', 'treatment received. The Double-blind Safety Population will be used to analyze all safety', 'endpoints collected during the Double-blind Phase, while the ITT Population will be used', 'to analyze all efficacy endpoints collected during the Double-blind Phase.', 'The Per-Protocol Population is defined as the subset of patients in the ITT Population', 'who do not have any major protocol deviations that could affect the efficacy analyses of', 'the double-blind data. An analysis of the primary and secondary efficacy variables for', 'the Per-Protocol Population will be performed.', 'Key exclusions from the Per-Protocol population include patients who:', 'Received less than 80% of the planned study drug doses', 'Had a mean baseline Worst Itching Intensity score <= 4.0', 'Had a missing average 24-hour weekly Worst Itching NRS score for >25% of', 'study weeks', 'Had significant amounts of restricted and prohibited medications (Section 6.4.9)', 'based on medical review', 'Received a different treatment than the treatment to which they were randomized', 'Inclusion in the Per-Protocol Population will be determined prior to unblinding the data.', 'The Open-label Safety Population is defined as the group of patients who receive at least', '1 dose of study drug in the Open-label Phase. The Open-label Safety Population will be', 'used to analyze all safety endpoints collected during the Open-label Phase, and during', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 63 of 95']"
61,page_62,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 62 of 92', 'CR845-CLIN3102', 'exposure to CR845 combining data from both the Double-blind and the', 'Open-label Phases.', '8.6', 'Statistical Summary and Analysis', '8.6.1', 'Patient Disposition', 'For the Double-blind Phase, the number of patients enrolled, treated, completed, or', 'discontinued from the study, along with the reason for discontinuation, will be', 'summarized overall and by treatment group.', 'For all categories of patients (except for the screened patients), percentages will be', 'calculated using the number of enrolled patients as the denominator.', 'In addition, the number of patients in each analysis population will be tabulated.', '8.6.2', 'Protocol Deviations', 'Protocol deviations will be identified in several ways: through programmatic checks,', 'through medical reviews, and by clinical research associates during site monitoring.', 'Protocol deviations will be classified as minor or major prior to the database lock. Major', 'protocol deviations will be summarized by treatment group. All protocol deviations will', 'be listed.', '8.6.3', 'Demographic and Baseline Characteristics', 'Demographic and baseline patient characteristics will be summarized overall and by', 'treatment group and will include age at screening, age category (<45, 45 to >65, 65 to', '<75, 75), gender, ethnicity, race, prescription dry body weight (kg). Height will not be', 'collected.', 'Baseline characteristics of the disease will also be summarized overall and by treatment', 'group, and will include variables such as etiology of chronic kidney disease, years since', 'ESRD, duration of pruritus, and time on chronic hemodialysis.', '8.6.4', 'Medical History', 'Medical history data will be coded using Medical Dictionary for Regulatory Activities', '(MedDRA) and summarized by MedDRA System Organ Class (SOC), Preferred Term,', 'and treatment group. The data will also be listed, including the verbatim investigator', 'description of the relevant medical condition, the coded terms (SOC, Preferred Term),', 'start date, end date, and whether or not the condition is ongoing.', 'A separate coding listing will be created with all the distinct levels of SOC, Preferred', 'Terms, and the verbatim investigator description reported in the study. Sorting will be', 'alphabetically by SOC, Preferred Term, and then verbatim description.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 64 of 95']"
62,page_63,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 63 of 92', 'CR845-CLIN3102', '8.6.5', 'Prior and Concomitant Medications', 'All medications will be coded using the World Health Organization Drug Dictionary. All', 'prior and concomitant medications will be listed and summarized separately by', 'Anatomical Therapeutic Chemical class 3 (ATC 3), Preferred Term, and treatment group.', 'The use of concomitant medications during the Double-blind and Discontinuation Period', 'will be summarized separately. Additionally, a coding listing of unique medications and', 'their corresponding coding will be presented.', '8.6.6', 'Antipruritic Medication', 'Prior and concomitant antipruritic medications will be summarized separately by study', 'period (Run-in, Double-blind, Discontinuation); summaries will be presented by', 'ingredient rather than by ATC codes.', '8.7', 'Efficacy Analysis', '8.7.1', 'Primary Efficacy Endpoint', 'The primary efficacy endpoint is defined as the proportion of patients achieving 3-point', 'improvement from baseline with respect to the weekly mean of the daily 24-hour Worst', 'Itching Intensity NRS at Week 12 (Days 79 to 85) of the Double-blind Treatment Period.', 'The weekly mean of the 24-hour Worst Itching Intensity NRS score will be defined as the', 'sum of the daily Worst Itching Intensity NRS scores reported during a specific week', 'during the Double-blind Treatment Period (eg, Days 2 to 8, Days 9 to 15, Days 16 to 22,', 'Days 79 to 85) divided by the number of days with nonmissing scores for that week. If', 'the daily worst itching score is missing for >3 days during a specific week, the', 'corresponding weekly mean worst itching score will be set to missing. The baseline', 'score will be defined as the average of the daily 24-hour Worst Itching Intensity NRS', 'scores collected over the Run-in Period, including pre-randomization assessments', 'collected on Day 1.', 'In the primary efficacy analysis, missing NRS data will be imputed using a multiple', 'imputation (MI) approach, assuming that patients who discontinue Double-blind', 'treatment early would have similar Worst Itching Intensity NRS scores as other patients', 'in their respective treatment arm that have complete data:', 'Intermittent missing NRS scores will first be imputed using the Markov Chain', 'Monte Carlo (MCMC) method implemented with the SAS MI procedure, which is', 'appropriate for non-monotonic missing data.', 'NRS scores missing after patients discontinue study drug early will then be', 'multiply imputed with the SAS MI procedure using a method appropriate for', 'monotone missingness (eg, regression statement). Details on the MI procedure', 'can be found in Appendix 14.8.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 65 of 95']"
63,page_64,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 64 of 92', 'CR845-CLIN3102', 'The proportion of patients who have an improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS score', '>3 points will be calculated for each imputed dataset. Differences between', 'CR845 0.5 mcg/kg and placebo with respect to the primary endpoint will be', 'compared using a logistic regression model containing terms for treatment group,', 'baseline NRS score, use of prior anti-itch medication, and presence of specific', 'medical conditions.', 'Results of the logistic regression on the multiply imputed data sets will be', 'summarized by the SAS MIANALYZE procedure.', 'The final p-value will be calculated using the Cui, Hung, Wang (CHW) procedure where', 'the z-score is a weighted average of the z-score at the interim and the z-score observed', 'for data collected after the interim, following the formula below.', 'Zfinal=Zinterim * V(n/N) + Zpost-interim * N(1 - n/N)', 'where n is the number of patients at the interim and N is the initial number of patients', 'planned (300).', 'Sensitivity analyses of the primary efficacy endpoint will be conducted to evaluate the', 'robustness of study results under different assumptions and imputation algorithms. For', 'each of these sensitivity analyses, the final p-value will be calculated based on the CWH', 'procedure, using the formula specified above.', 'Sensitivity 1: Early discontinuations as nonresponders', 'Patients who discontinue study drug early will be considered nonresponders. The', 'imputed data will be analyzed using a logistic regression model similar to the', 'primary analysis.', 'Sensitivity 2: Multiple imputation; missing not at random (MNAR)', 'This sensitivity analysis is an implementation of a pattern mixture model that', 'draws from different populations based on the reason for withdrawal.', 'Intermittent missing NRS scores will first be imputed using the MCMC', 'method with the SAS MI procedure, which is appropriate for non-monotonic', 'missing data.', 'For patients who discontinued study drug due to adverse events, NRS scores', 'missing after discontinuation will be imputed using the distribution of the', ""baseline value of all patients' daily worst itching score assuming a trimmed"", 'normal (from 4 to 10).', 'For patients who discontinue due to reasons other than adverse event, missing', 'NRS scores after patients discontinue study drug early will be multiply', 'imputed using multiple calls of the SAS MI procedure using data from', 'patients within the same treatment group that have complete data at that time.', 'The proportion of patients who have an improvement from baseline with', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 66 of 95']"
64,page_65,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 65 of 92', 'CR845-CLIN3102', 'respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS', 'score >3 points will be calculated for each imputed dataset', 'Similar to the primary analysis, results of the logistic regression on the', 'multiply imputed data sets will be summarized by the SAS MIANALYZE', 'procedure.', 'Sensitivity 3: (Tipping point analysis', 'Multiple imputation with mixed missing data mechanisms (MNAR for a missing', 'data pattern and MAR for others) will be used to assess the robustness of the', 'MAR assumption. This sensitivity analysis is to investigate the departure from', 'MAR assumption by progressively decreasing the treatment differences with', 'respect to the NRS scores over the missing visits in active treatment group until', 'conclusion from the primary analysis is overturned. The MI procedure includes', 'the following steps:', 'Uses MCMC methodology from PROC MI by treatment group to impute the', 'intermittent missing data to a monotone missing pattern', 'Uses a standard MAR-based MI approach from PROC MI to impute data from', 'monotone missing data', 'For patients in the active treatment group, shift parameter from PROC MI will', 'be progressively applied to impute the missing data, until the p-value >0.05', 'To evaluate the potential impact of the IA on the properties of statistical inference at the', 'end of the trial, the primary and sensitivity analyses of the primary endpoint will also be', 'presented separately for the sample of patients enrolled into the study after the IA.', '8.7.2', 'Secondary Efficacy Enppoints', 'The secondary efficacy endpoints are the:', 'Change from baseline in itch-related quality of life at the end of Week 12 of the', 'Double-blind Treatment Period, as assessed by the 5-D Itch Scale total score;', 'Change from baseline in itch-related quality of life at the end of Week 12 of the', 'Double-blind Treatment Period, as assessed by the total Skindex-10 Scale total', 'core;', 'Proportion of patients achieving >4-point improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12', '(Day 79 to 85) of the Double-blind Treatment Period.', 'The 5-D Itch Scale and the Skindex-10 Scale score will be analyzed using a mixed effects', 'model with repeated measures (MMRM). The model will contain treatment, week, and', 'treatment-by-week interaction as fixed effects; baseline score, prior anti-itch medication', 'usage and presence of specific medical conditions as covariates; and patient as a random', 'effect. The baseline 5-D total score and the Skindex-10 total score will be defined as the', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 67 of 95']"
65,page_66,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 66 of 92', 'CR845-CLIN3102', 'value collected on Day 1, prior to randomization. Repeated measures will include values', 'collected at the end of Weeks 4, 8, 10, and 12 (end of treatment). The mean treatment', 'difference between CR845 0.5 mcg/kg and placebo will be estimated as the simple', 'contrast in the treatment effect at Double-blind Treatment Period Week 12.', 'It is important to note that, in HD patients, the study drug administered during the last', 'dialysis of a particular week is not cleared until the first dialysis of the next week.', 'Therefore, measurements that would reflect treatment effect at the end of a specific week', '(eg. Week 4) will actually be collected during the first day of the next week (eg, Week 5).', 'For the analysis of 5-D Itch Scale and the Skindex-1( Scale score, an appropriate', 'covariance matrix will be used to model the within-patient errors. The use of an', 'unstructured covariance matrix structure as well as other structures, such as spatial', 'patterns, that require fewer parameters (Toeplitz, autoregressive, or compound symmetry)', 'will be examined. The Akaike information criterion will be used to determine the', 'appropriate covariance matrix for the MMRM. The Kenward-Roger approximation will', 'be used to estimate the denominator degrees of freedom. Missing scores will not be', 'imputed. Assuming that the data are MAR, the estimates of the treatment differences', 'calculated from the MMRM described above are unbiased.', 'The proportion of patients achieving >4-point improvement from baseline with respect to', 'the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12 of the', 'Double-blind Treatment Period will be analyzed following a methodology similar to the', 'one employed for the primary analysis of the primary endpoint.', '8.7.3', 'Hypothesis Testing Strategy', 'The efficacy of CR845 0.5 mcg/kg compared to placebo in pivotal Phase 3 study', 'CLIN3102 will be evaluated based on 1 primary and 3 secondary efficacy endpoints.', 'Testing of the primary efficacy endpoint will be 2-sided and conducted at the 5% error', 'level. The study will be considered positive if the null hypothesis of no treatment', 'difference in the primary efficacy analysis of the primary endpoint (proportion of patients', 'achieving >3-point improvement from baseline with respect to the Worst Itching Intensity', 'NRS) is rejected in favor of the alternative that patients randomized to CR845 experience', 'significantly less itching compared to patients randomized to placebo.', 'To protect the Type 1 error, a gate-keeping strategy will be implemented. Although the', 'p-values corresponding to the hypothesis testing of the secondary variables will be', 'reported, they will only be considered inferential if the primary analysis is statistically', 'significant. Testing of the 2 secondary efficacy endpoints will be performed sequentially', 'at a 2-sided 5% error level. The difference between CR845 0.5 mcg/kg and placebo with', 'respect to the 5-D Itch total score will be tested first. If results are statistically significant', 'in favor of CR845, testing with respect to the Skindex-10 total score will proceed and be', 'inferential.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 68 of 95']"
66,page_67,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 67 of 92', 'CR845-CLIN3102', 'The proportion of patients achieving >4-point improvement from baseline with respect to', 'the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12 of the', 'Double-blind Treatment Period will be tested only if the results of Skindex-10 total score', 'are statistically significant in favor of CR845.', '8.7.4', 'Additional Efficacy Enppoints', '8.7.4.1', 'Itch-intensity Measures', 'Proportion of patients who have an improvement from baseline at Week 12 of the', 'Double-blind period with respect to the weekly mean of the 24-hour Worst', 'Itching Intensity NRS scores 1 and >2. The calculation of the proportions will', 'be based on the NRS data using a multiple imputation (MI) approach for the', 'missing data as in the primary efficacy analysis. A figure presenting the', 'proportion of patients who have an improvement from baseline in NRS scores at', 'Week 12 that is >1, >2, >3, and >4 will be prepared.', 'Change from baseline in the weekly mean of the 24-hour Worst Itching Intensity', 'NRS score at each week of the Double-blind Treatment Period (Week 1 to', 'Week 12). Treatment differences between CR845 and placebo at each', 'postbaseline time point will be evaluated using the same MMRM detailed in', 'Section 8.7.2.', 'Proportion of patients who rate their itch condition as ""Very much improved""', 'or', '""Much Improved"" at the end of Week 12 of the Double-blind Treatment', 'Period/end of double-blind treatment, as measured by the Patient Global', 'Impression of Change. Treatment difference will be tested using the Cochran-', ""Mantel-Haenszel test, adjusting for strata. An exact test, such as the Fisher's"", 'Exact Test, may be used if the observed count in a particular cell is small (ie, <5).', '8.7.4.2', 'Itch-related Quality-of-Life Measures', 'Itch-related quality-of-life measures and their analyses will include:', 'Change from baseline in itch-related quality of life at each week of the', 'Double-blind Treatment Period, as assessed by the 5-D Itch Scale total score.', 'Treatment differences between CR845 and placebo at each postbaseline time', 'point will be evaluated using the same MMRM fitted for the secondary efficacy', 'analysis.', 'Change from baseline in itch-related quality-of-life at each week of the', 'Double-blind Treatment Period, as assessed by the Skindex-10 Scale total score.', 'Treatment differences between CR845 and placebo at each postbaseline time', 'point will be evaluated using the same MMRM fitted for the secondary efficacy', 'analysis.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 69 of 95']"
67,page_68,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 68 of 92', 'CR845-CLIN3102', 'Change from baseline in itch-related quality of life at Week 12 of the', 'Double-blind Treatment Period and at each of the remaining weeks of the', 'Double-blind Treatment Period with respect to each of the 3 domains of the', 'Skindex-10 Scale. Treatment differences with respect to each domain will be', 'evaluated using a model similar to the MMRM fitted for the analysis of the', 'change from baseline in the overall Skindex-10 Scale score (Section 8.7.2).', '8.8', 'Safety Analysis', 'Analysis of all safety data collected during the Double-blind Phase will be performed on', 'the Double-blind Safety Population. The SAP will provide further detail for the analyses', 'to be applied to each safety parameter, and will also include analyses of safety data', 'collected during the Open-label Phase and during exposure to CR845 during both the', 'Double-blind and Open-label Phases. No statistical hypothesis testing will be carried out', 'and no inferential statistical analysis of the safety parameters will be performed.', 'The baseline value for all analyses of double-blind safety parameters will be defined as', 'the last value obtained prior to the first dose of double-blind study drug and will include', 'both scheduled and repeat (unscheduled) observations.', '8.8.1', 'Exposure to Study Drug', 'For this study, the duration of double-blind treatment for each individual patient may be', 'up to 12 weeks, for a total of approximately 36 doses of study drug administered', 'immediately following each dialysis session. Day 1 of the Double-blind Treatment', 'Period will be defined as the day of administration of the first dose of study drug. The', 'last day of the Double-blind Treatment Period will be defined as the day of the dialysis', 'session immediately following the last injection of study drug.', 'Exposure and treatment compliance during the Double-blind Treatment Period will be', 'summarized by the following parameters:', 'Duration of treatment (days)', 'Total number of doses actually received', 'Number of missed doses', 'Duration of treatment (days) = (date of first dialysis after last dose) - (date of first dose)', '+ 1.', 'If a patient receives additional dialysis during a given week for any reason, an additional', 'dose of CR845 will be administered following dialysis. A maximum of 4 doses per week', 'is allowed. No additional doses will be given for patients receiving an additional', 'unscheduled ultrafiltration treatment. The number of patients getting such an extra', 'treatment will be summarized.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 70 of 95']"
68,page_69,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 69 of 92', 'CR845-CLIN3102', '8.8.2', 'Adverse Events', 'All adverse events, as reported by the site, will be coded using MedDRA to MedDRA', 'SOC and Preferred Term for standardization and summary purposes.', 'All reported adverse events (whether or not treatment-emergent) will be included in a', 'by-patient adverse event listing. Only TEAEs will be included in summary tables which', 'will present results by treatment group and by study period, as appropriate.', 'Adverse events that are considered ""treatment emergent"" relative to the Run-in Period are', 'identified as any adverse event with an onset date after the start of the Run-in Period and', 'up to the first dose of study drug during the Double-blind Period.', 'Adverse events that are considered ""treatment emergent"" relative to the Double-blind', 'Period are identified as any adverse event with an onset date after the first dose of the', 'double-blind study drug up to the study Double-blind End of Treatment/Early', 'Termination Visit or the start of the Discontinuation Period (or 7 to 10 days after the last', 'dose if no Double-blind End of Treatment/Early Termination Visit was conducted),', 'whichever is later', 'Adverse events that are considered ""treatment-emergent"" relative to the Discontinuation', 'Period are identified as any adverse event with an onset date after and up to 2 weeks post', 'the start of the Discontinuation Period or the start of the Open-label Phase, whichever', 'comes first', 'The number and percentage of patients experiencing TEAEs will be summarized by', 'treatment group and by period. A patient will be counted only once in the incidence', 'count for a MedDRA SOC or Preferred Term, although a patient may have multiple', 'occurrences (start and stop) of an event associated with a specific MedDRA Preferred', 'Term or SOC. The most frequent TEAEs (5% of patients in any treatment group) will', 'also be tabulated by SOC and Preferred Term.', 'The incidence and percentage of patients experiencing treatment-emergent SAEs and', 'TEAEs leading to study discontinuation will be presented by the appropriate MedDRA', 'SOC and Preferred Term. Adverse events that result in death will also be summarized.', 'Treatment-emergent adverse events will also be summarized by severity for each study', 'period of the Double-blind Phase and by relationship to double-blind study drug for the', 'Double-blind Period. If the severity and/or relationship to the study drug of an adverse', 'event is missing, a worst-case scenario will be assumed (ie, the adverse event will be', 'categorized as ""severe"" and/or ""related"" to the study drug). If a patient reports the same', 'TEAE multiple times the event with the worst severity and the strongest relationship to', 'study drug will be tabulated.', 'Separate tables summarizing the incidence of AESIs, as defined in the Safety', 'Surveillance plan, will be presented for each study period.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 71 of 95']"
69,page_70,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 70 of 92', 'CR845-CLIN3102', 'In addition, to evaluate the potential for physical dependence of CR845, a summary table', 'comparing the incidence rate of TEAEs occurring prior to (i.e. during the Double-blind', 'Period) and during the Discontinuation Period will be presented.', 'For each period of the Double-blind Phase, an overall summary table will be provided,', 'presenting for each treatment group: the number and percentage of patients with an', 'adverse event (both treatment and non-treatment emergent) during that period, a TEAE,', 'serious TEAE, related TEAE, severe TEAE, TEAE leading to dose interruption, and', 'TEAE leading to study drug discontinuation. This table will also include the number of', 'events for each specific Preferred Term.', 'All adverse events will be listed in chronological order, including patient identifier, age,', 'race, gender, a flag indicating whether the event was treatment-emergent, and all related', 'event status information (start and stop dates, whether the event was ongoing, study day', 'of onset, severity, seriousness, relationship to study medication, action taken with study', 'treatment, and outcome). Separate listings will be generated for SAEs, deaths, and', 'adverse events leading to study drug discontinuation. Additionally, a coding list of', 'Preferred Terms and the verbatim text associated with them will be produced.', '8.8.3', 'Clinical Laboratory Evaluations', 'Summary statistics for each scheduled time point measured and mean changes from', 'baseline to each time point (when applicable) will be presented for clinical laboratory', 'results.', 'All laboratory evaluation summaries will include the patients in the Double-blind Safety', 'Population who have at least 1 postbaseline time point (for criteria based on postbaseline', 'assessments) and with both a baseline and at least 1 postbaseline time point (for criteria', 'evaluating changes from baseline).', 'Laboratory values will be reported in Systme International units.', 'Laboratory test results will be assigned an L/N/H classification according to whether the', ""value was below (L), within (N), or above (H) the laboratory parameter's reference range."", 'Comparisons will be based on 3x3 tables (shift tables) that, for a particular laboratory', 'test, compare the baseline L/N/H classification to the highest and/or lowest L/N/H', 'classification during the treatment period. Clinically important laboratory values based', 'on prespecified criteria defined in the SAP will also be summarized.', 'Additionally, alanine aminotransferase, aspartate aminotransferase, bilirubin, and alkaline', 'phosphatase will be presented in a separate listing, with 3x and 5xULN flagged for', 'alanine aminotransferase and aspartate aminotransferase; 2xULN flagged for bilirubin,', 'and 1.5xULN flagged for alkaline phosphatase.', '8.8.4', 'Vital Signs and ECGs', 'Summary tables will include descriptive statistics for baseline and each postbaseline', 'assessment. Descriptive statistics will be calculated on both the actual score and the', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 72 of 95']"
70,page_71,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 71 of 92', 'CR845-CLIN3102', 'change from baseline score. Baseline is defined as the last measurement taken on or prior', 'to the first day of dosing. Note that the Day 1 assessment can be included in the', 'evaluation of baseline if that the assessment is performed prior to dosing.', 'If or more evaluations occur in the same visit window, the evaluation closest to the', 'target visit day will be selected for inclusion in the analysis. If multiple evaluations are', 'equally close to the target visit day, then the latest evaluation will be selected for', 'inclusion in the analysis.', 'All vital sign summaries will include the patients in the Double-blind Safety Population', 'who have at least a postbaseline time point (for criteria based on postbaseline', 'assessments) and with both a baseline and at least 1 postbaseline time point (for criteria', 'evaluating changes from baseline). >', 'Clinically notable vital signs will be identified based on the criteria in Table 6. For each', 'vital sign parameter, the number and percentage of patients with at least 1 notable value', 'will be tabulated by week and overall for the Double-blind Phase.', 'Table 6.', 'Criteria Used to Identify Clinically Notable Vital Sign', 'Abnormalities', 'Vital Sign Parameter', 'Value', 'Change from Baselinea', 'Systolic blood pressure', '>180 mm Hg', 'Increase or Decrease of >40 mm Hg', '<90 mm Hg', 'Decrease of >60 mm Hg', 'Diastolic blood pressure', '>100 mm Hg', 'Increase or Decrease of >20 mm Hg', '<60 mm Hg', 'Decrease of >40 mm Hg', 'Heart rate', '>130 bpm', 'Increase of >30 bpm', '<55 bpm', 'Decrease of >30 bpm', 'a.', 'Both value and change from baseline criteria must be met to qualify as a clinically notable', 'abnormality.', 'All vital signs will be listed in by-patient listings, including visit and collection date/time,', 'and will be sorted by patient identifier and date/time of assessment.', 'Electrocardiogram results include an overall interpretation of ""normal, \'abnormal but not', ""clinically significant,' or 'abnormal and clinically significant. These results will be"", 'tabulated at each time point.', 'Electrocardiogram results will be listed for each visit, including visit, whether ECG was', 'performed (yes/no), explanation (if not performed), assessment date/time, study date,', 'overall interpretation, and relevant medical history number or adverse event number, if', 'deemed a clinically significant abnormality.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 73 of 95']"
71,page_72,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 72 of 92', 'CR845-CLIN3102', '8.9', 'Additional Analyses', '8.9.1', 'Inflammatory Biomarkers', 'The observed value and the change in inflammatory biomarkers (eg, IL-6, IL-8, and', 'granulocyte macrophage-colony stimulating factor) from pre-dose to the end of the', 'Double-blind Treatment Period (Week 12) will be presented by treatment group.', 'Univariate and multivariate analyses of the change in inflammatory biomarkers will be', 'described in an analysis plan, separate from the study SAP.', '8.9.2', 'Missed Dialysis Visits and Incidence of Infection', 'The number and percentage of patients who missed 1 or more dialysis visits during the', 'Double-blind Treatment Period, and the total number of missed dialyses visits will be', 'tabulated overall and by treatment group.', 'Incidence of infections based on adverse events, hospitalizations, and/or use of antibiotics', ""for treatment of infection related to uremic pruritus will be analyzed using Fisher's Exact"", 'Test.', '8.9.3', 'ESA and IV Iron', 'Erythropoiesis-stimulating agent and IV Iron use will be summarized descriptively by', 'treatment group. Statistical analyses of changes in use of ESAs or IV iron from pre-dose', 'to the end of the Double-blind Treatment Period (Week 12) will be defined in the SAP.', '8.9.4', 'Discontinuation Period Additional Assessments', 'Baseline ShOWS and OOWS will be the scores collected on the dialysis day on Day 85', '(Double-blind EOT/Early Termination) (Table 2). Only patients who have a baseline', 'ShOWS and OOWS will be included in the analysis.', 'Summary statistics for the daily ShOWs and the OOWS collected at each dialysis visit,', 'including number of non-missing observations, mean, standard deviation, median,', 'minimum, and maximum median of ShOWS and OOWS will be tabulated by treatment', 'group. Figures for the overall mean scores over time will also be presented.', 'The ShOWS scores on discontinuation days 1, 2, 3, and >3 will be analyzed to compare', 'the treatment groups at each visit, using an Analysis of Covariance (ANCOVA) model,', 'with treatment group and baseline value as a covariate. The OOWS scores will be', 'analyzed using a similar ANCOVA model at each day of collection. In addition,', 'between-treatment group comparisons over the overall 2-Week Discontinuation Period', 'will be performed using an MMRM with treatment group, discontinuation day, and', 'treatment group-by-day interaction as fixed effects, baseline value as the covariate, and', 'patient as a random effect. An unstructured covariance matrix will be used to model the', 'covariance of within-patient scores. These analyses will be performed based on all', 'postbaseline scores using only the observed cases without imputation of missing values.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 74 of 95']"
72,page_73,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 73 of 92', 'CR845-CLIN3102', 'Exploratory analyses may be performed, depending on sample size, for the subgroup of', 'patients who also stop taking concomitant opioid medications during the 2-week', 'Discontinuation Period.', 'Adverse events (AEs) and vital signs potentially related to withdrawal that occur during', 'the 2-week Discontinuation Period will be identified based on a blinded review of the', 'data, and will be summarized by randomized treatment group, and compared to the', '2-week period prior to discontinuation,', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 75 of 95']"
73,page_74,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 74 of 92', 'CR845-CLIN3102', '9.0', 'Quality Control and Quality Assurance', '9.1', 'Study Monitoring Plan', 'Monitoring and auditing procedures that comply with current Good Clinical Practice', '(GCP) guidelines will be followed, including remote and onsite review of the eCRFs via', 'an electronic data capture system for completeness and clarity, source document', 'verification, evaluation of protocol adherence, appropriate documentation of informed', 'consent procedures, safety reporting, study drug storage, and dispensation. The study', 'will be monitored by Cara Therapeutics or its designee (contract research organization).', 'Monitoring will be done remotely or by personal visits from a representative of the', 'Sponsor or its designee (site monitor) who will review patient enrollment, eCRFs, source', 'documents, drug accountability records, and reporting and recording of adverse events.', 'The site monitor will ensure that the investigation is conducted according to protocol', 'design and regulatory requirements by frequent site visits and communications (letter,', 'telephone, and facsimile).', 'The site monitor(s) will follow written standard operating procedures as agreed with the', 'contract research organization and the Sponsor. The site monitor(s) will verify that the', 'clinical study is conducted and data are generated, documented (recorded), and reported', 'in compliance with the protocol, GCP, and the applicable regulatory requirements.', 'Monitoring reports will be submitted to the Sponsor in a timely fashion as per details', 'described in a clinical monitoring plan for this study.', 'Name and contact information for monitors will be included in the ISF.', 'An IDMC will be convened for this study to implement an unblinded sample size', 're-estimation. In addition, there will be a DSMB that will convene periodically to assess', 'accumulating safety data. Membership into the IDMC will be independent of', 'membership into the DSMB. A contract organization specializing in IDMC management', ""will be identified. The IDMC and the DSMB will be supported on the Sponsor's behalf"", 'by an independent unblinded statistician who will not be part of the study team. Details', 'will be in the IDMC and DSMB charters.', 'Clinical laboratory testing will be completed at a central laboratory. The central', 'laboratory will provide a separate manual.', '9.2', 'Audits and Inspections', 'The investigational site will maintain appropriate medical and research records for this', 'study, in compliance with ICH-GCP, regulatory, and institutional requirements for the', 'protection of confidentiality of participants. The Investigator must allow access to', 'authorized persons or institutions to complete data source verification. Source data are', 'all information, original records of clinical findings, observations, or other activities in a', 'clinical study necessary for the reconstruction and evaluation of the study. Examples of', 'these original documents and data records include, but are not limited to, hospital records,', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 76 of 95']"
74,page_75,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 75 of 92', 'CR845-CLIN3102', ""clinical and office charts, laboratory notes, memoranda, participants' diaries or evaluation"", 'checklists, pharmacy dispensing records, recorded data from automated instruments,', 'copies or transcriptions certified after verification as being accurate and complete,', 'microfiches, photographic negatives, microfilm or magnetic media, x-rays, and', 'participant files and records kept at the pharmacy, laboratories, or medical-technical', 'departments involved in the clinical study, as applicable.', 'The investigational site will provide access to all study-related sites, source', 'data/documents, and reports for the purpose of monitoring and auditing by the Sponsor', 'and inspection by local and regulatory authorities.', '9.3', 'Data Collection, Validation, and Analysis', 'A data management vendor will ensure that quality assurance procedures are', 'implemented, beginning with the data entry system and generation of data quality control', 'checks that will be run on the database.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 77 of 95']"
75,page_76,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 76 of 92', 'CR845-CLIN3102', '10.0', 'Ethics and Regulatory Compliance', '10.1', 'Independent Ethics Committee or Institutional Review Board', 'A properly constituted, valid IRB or Independent Ethics Committee must review and', ""approve the protocol, the Investigator's Brochure, ICF, and related patient information"", 'and recruitment materials (if applicable) before the start of the study. It is the', 'responsibility of the Investigator to ensure that written informed consent is obtained from', 'the patient before any activity or procedure is undertaken that is not part of routine care.', 'The IRB will review all appropriate study documentation in order to safeguard the rights,', 'safety, and well-being of the patients. The study will only be conducted at a site where', 'IRB approval has been obtained. The protocol, IB, ICF, advertisements (if applicable),', 'written information given to the patients, safety updates, annual progress reports, and any', 'revisions to these documents will be provided to the IRB by the Investigator.', 'If it is necessary to amend the protocol and/or ICF during the course of the study, the', 'Investigator must ensure that the IRB reviews and approves these amended documents.', 'Except for changes necessary to eliminate an immediate hazard to study patients, or when', 'the change involves only logistical or administrative aspects of the study (eg, change in', 'monitor, change of telephone number), no amendments to the study protocol will be', 'made without the prior written agreement of the Sponsor and acknowledgement by the', 'Investigator and, as applicable, the IRB.', 'The Investigator(s) will maintain documentation of the composition of the IRB as well as', 'all correspondence with the IRB. The Investigator(s) will comply with local', 'requirements for routine reporting to the IRB as well as local and government', 'requirements for notifying the IRB of SAEs. The Investigator will provide Cara', 'Therapeutics or its designee copies of all IRB approval notices, correspondence, annual', 'reports, and final study progress reports.', '10.2', 'Ethical Conduct of the Study', 'The study will be conducted in accordance with ethical principles founded in the', 'Declaration of Helsinki and all accepted amendments, the ICH principles of GCP', '(including archiving of essential study documents) and the applicable regulations of the', 'country in which the study is conducted.', 'The Investigator will be thoroughly familiar with the appropriate use of the study drug as', ""described in the protocol, Investigator's Brochure, and any other study-related manual(s)"", 'Essential clinical documents will be maintained to demonstrate the validity of the study', 'and the integrity of the data collected. A study master file must be established for the', 'study, and retained according to the appropriate regulations.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 78 of 95']"
76,page_77,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 77 of 92', 'CR845-CLIN3102', '10.3', 'Informed Consent Process', 'Informed consent is required for all patients participating in this study. In obtaining and', 'documenting informed consent, the Investigator must comply with applicable regulatory', 'requirements and must adhere to GCP regulations. It is the responsibility of the', 'Investigator to ensure that written informed consent is obtained from the patient before', 'any activity or procedure is undertaken that is not part of routine care.', ""Informed consent is a process that is initiated prior to the individual's agreeing to"", ""participate in the study and that continues throughout the individual's study participation."", 'The Investigator or designee will discuss extensively with the participant patient the', 'study risks. Copies of the current, IRB-approved ICF detailing the risks and benefits of', 'study participation will be provided to the participants. Consent forms describing in', 'detail the study drug and study procedures/intervention and risks will be fully explained', 'to the patient and written documentation of informed consent will be required prior to', 'starting participation in the study. Upon reviewing the document, the Investigator or', 'designee will explain the research study to the participant and answer any questions that', 'may arise. The participants will sign the ICF prior to any procedures being done', 'specifically for the study. The participants should have sufficient opportunity to discuss', 'the study and process the information in the consent process prior to agreeing to', 'participate. The participants may withdraw consent at any time throughout the course of', 'the study. A signed copy of the ICF will be given to the participants for their records.', 'Patients must sign a separate informed consent prior to participating in the Open-label', 'Treatment Period.', '10.4', 'Patient Confidentiality', 'In order to maintain patient privacy, all eCRFs, study drug accountability records, study', 'reports, and communications will identify the patient by assigned patient number. The', 'Investigator will grant monitor(s) and auditor(s) from the Sponsor or its designee and', ""regulatory authority(ies) access to the patient's original medical records for verification"", ""of data gathered on the eCRFs and to audit the data collection process. The patient's"", 'confidentiality will be maintained and will not be made publicly available to the extent', 'permitted by the applicable laws and regulations.', 'Participant confidentiality is strictly held in trust by the participating Investigators, their', 'staff, and the Sponsor(s) and their agents. This confidentiality is extended to cover', 'testing of biological samples and genetic tests in addition to the clinical information', 'relating to participating patients.', 'The study protocol, documentation, data, and all other information generated will be held', 'in strict confidence. No information concerning the study or the data will be released to', 'any unauthorized third party without prior written approval of the Sponsor.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 79 of 95']"
77,page_78,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 78 of 92', 'CR845-CLIN3102', 'The study monitor or other authorized representatives of the Sponsor may inspect all', 'documents and records required to be maintained by the Investigator, including, but not', 'limited to, medical records (office, clinic, or hospital) and pharmacy records for the', 'participants in this study.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 80 of 95']"
78,page_79,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 79 of 92', 'CR845-CLIN3102', '11.0', 'Data Handling and Quality Assurance', 'All participant data relating to the study will be recorded on eCRFs unless transmitted to', 'the Sponsor or designee electronically (eg, laboratory data). No data are to be recorded', 'directly in the eCRFs (eg, all data will have a unique source). The Investigator is', 'responsible for verifying that data entries are accurate and correct by physically or', 'electronically signing the eCRF.', 'The Investigator must maintain accurate documentation (source data) that supports the', 'information entered in the eCRF.', 'The Investigator must permit study-related monitoring, audits, IRB/Independent Ethics', 'Committee review, and regulatory agency inspections and provide direct access to source', 'data documents.', 'The Sponsor or designee is responsible for the data management of this study, including', 'quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that data entered', 'into the eCRF by authorized site personnel are accurate, complete, and verifiable from', 'source documents; that the safety and rights of participants are being protected; and that', 'the study is being conducted in accordance with the currently approved protocol and any', 'other study agreements, ICH-GCP, and all applicable regulatory requirements.', 'Records and documents, including signed ICFs, pertaining to the conduct of this study', 'must be retained by the Investigator for 2 years after the marketing approval of the study', 'drug or after discontinuing clinical development unless local regulations or institutional', 'policies require a longer retention period. No records may be destroyed during the', 'retention period without the written approval of the Sponsor. No records may be', 'transferred to another location or party without written notification to the Sponsor. If the', 'Investigator withdraws from the responsibility of keeping the study records, custody must', 'be transferred to a person willing to accept the responsibility. If a custodial change or a', 'change in record location occurs, Cara Therapeutics must be notified in writing.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 81 of 95']"
79,page_80,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 80 of 92', 'CR845-CLIN3102', '12.0', 'Administrative Procedures', '12.1', 'Protocol Adherence', 'It is vital to the success of the study that the Investigator adhere to the details of the', 'protocol, and thus to keep to a minimum the number of cases later classified as', '""incomplete,"" ""unusable,"" or ""not evaluable."" If, in the interest of safety and/or', 'well-being of a particular patient, it is necessary to depart from the protocol, then that', 'protocol deviation will pertain to that individual patient only and will be documented.', 'Protocol deviations due to lack of patient compliance must also be documented.', 'The site monitor will review protocol deviations throughout the course of monitoring', 'visits and document new findings of deviations. The monitor will notify the Investigators', 'of deviations verbally or in writing. The IRB should be notified of all protocol deviations', 'in a timely manner according to IRB requirements.', '12.2', 'Publication of Study Findings', 'All information regarding CR845 provided by Cara Therapeutics to the Investigator is', 'privileged and confidential information. By conducting this study, the Investigator', 'affirms to the Sponsor that he/she will maintain, in strict confidence, information', 'furnished by the Sponsor, including data generated from this study and preliminary', 'laboratory results, except as exempted for regulatory purposes. All data generated during', 'the conduct of this study are owned by Cara Therapeutics. The Investigator agrees to use', 'the information to accomplish the study and will not use it for other purposes without', 'written permission from Cara Therapeutics. Partial or full data or results from this study', 'cannot be published without express written consent from Cara Therapeutics. It is', 'understood that there is an obligation to provide Cara Therapeutics with complete data', 'obtained during the study. The information obtained from the clinical study will be used', 'toward the development of CR845 and may be disclosed to regulatory authority, other', 'Investigators, corporate partners, or consultants, as required.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 82 of 95']"
80,page_81,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 81 of 92', 'CR845-CLIN3102', '13.0', 'References', 'Bradley BP, Gossop M, Phillips GT, Legarda JJ. The development of an opiate', 'withdrawal scale (OWS). Br J Addict. 1987;82(10):1139-4', 'Chang M. Conditional error function method and conditional power. In: Adaptive Design', 'Theory and Implementation Using SAS and R. Second edition. Boca Raton, FL:', 'Chapman and Hall/CRC; 2014; p. 183-98.', 'Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical', 'trials. Biometrics. 1999;55(3):853-7.', 'Criteria Committee of the New York Heart Association. Nomenclature and Criteria for', 'Diagnosis of Diseases of the Heart and Great Vessels. Edition Number 9. Little, Brown &', 'Co; Boston, Mass: 1994. pp. 253-6.', 'Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical', 'trials: IMMPACT recommendations. Pain. 2005;113(1-2):9-19.', 'Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus.', 'Br J Dermatol. 2010;162(3):587-93.', 'Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict', 'Behav. 1990;15(5): 487-90.', 'Guidance for Industry. Assessment of Abuse Potential of Drugs. US Department of', 'Health and Human Services, Food and Drug Administration, Center for Drug Evaluation', 'and Research (CDER). January 2017.', 'Guidance for Industry. Determining the extent of safety data collection needed in late-', 'stage premarket and postapproval clinical investigations. US Department of Health and', 'Human Services, Food and Drug Administration, Center for Drug Evaluation and', 'Research (CDER), Center for Biologics Evaluation and Research (CBER). February', '2016.', 'Handelsman L, Cochrane KJ, Aronson MJ, Ness RA, Rubinstein KJ, Kanof PD. Two', 'new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308.', ""Investigator's Brochure. CR845 (Difelikefalin). Edition Number 7. 19 May 2016."", 'Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the', 'pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant.', '2006;21(3):749-55.', 'Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a', 'novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in', '337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled', 'study. NDT. 2010;25(4):1251-7', 'Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in', 'hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(8):1410-9.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 83 of 95']"
81,page_82,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 82 of 92', 'CR845-CLIN3102', 'Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus-new perspectives and', 'insights from recent trials. Nephrol Dial Transplant. 2002;17(9): 1558-63.', 'Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic', 'pruritus in chronic hemodialysis patients. Kidney Int. 2006;69(9):1626-32.', 'Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD.', 'Am J Kidney Dis. 2007;50(1):11-20.', 'Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on', 'validity and reliability of the visual analogue scale, numerical rating scale and verbal', 'rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-7', 'Pisoni RL, Wikstrom B, Elder SJ, et al. Pruritus in haemodialysis patients: International', 'results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial', 'Transplant. 2006;21(12):3495-505.', 'Stnder S, Augustin M, Reich A, et al. Pruritus Assessment in clinical trials: consensus', 'recommendations from the International Forum for the Study of Itch (IFSI) Special', 'Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol. 2013;93(5):509-14.', 'Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J', 'Dermatol. 2011;165(1): 5-17.', 'Vernon MK, Reinders S, Mannix S, Gullo K, Gorodetzky CW, Clinch T. Psychometric', 'evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in', 'patients undergoing opioid detoxification. Addict Behav. 2016;60:109-16.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 84 of 95']"
82,page_83,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 83 of 92', 'CR845-CLIN3102', '14.0', 'Appendix', '14.1', 'Appendix 1: New York Heart Association Classification of Heart', 'Failure', 'New York Heart Association (NYHA) Classification of Heart Failure', 'Class', 'Patient Symptoms', 'Class I (Mild)', 'No limitation of physical activity. Ordinary physical activity', 'does not cause undue fatigue, rapid/irregular heartbeat', '(palpitation) or shortness of breath (dyspnea).', 'Class II (Mild)', 'Slight limitation of physical activity. Comfortable at rest, but', 'ordinary physical activity results in fatigue, rapid/irregular', 'heartbeat (palpitation) or shortness of breath (dyspnea).', 'Class III (Moderate)', 'Marked limitation of physical activity. Comfortable at rest,', 'but less than ordinary activity causes fatigue, rapid/irregular', 'heartbeat (palpitation) or shortness of breath (dyspnea).', 'Class IV (Severe)', 'Unable to carry out any physical activity without discomfort.', 'Symptoms of fatigue, rapid/irregular heartbeat (palpitation)', 'or shortness of breath (dyspnea) are present at rest. If any', 'physical activity is undertaken, discomfort increases.', '[Criteria Committee of the New York Heart Association 1994]', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 85 of 95']"
83,page_84,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 84 of 92', 'CR845-CLIN3102', '14.2', 'Appendix 2: Worst Itching Intensity Numerical Rating Scale', '(NRS)', 'This is a representation of the content of the instrument to be used. Please refer to the', 'Study Reference Manual for the instrument to be administered to patients and', 'instructions.', 'Completed in Dialysis Unit or at Home? (please mark only one)', 'Dialysis Unit', 'Home', 'INSTRUCTIONS', 'Please indicate the intensity of the WORST ITCHING you experienced over the', 'past 24 hours by marking the box with the number that best describes it. After', 'completing the scale below, please provide your initials in the SUBJECT INITIALS', 'box indicating that you completed the scale by yourself and the DATE and TIME', 'you completed the scale.', 'Worst Itching Over the Past 24 Hours', 'Please indicate the intensity of the WORST ITCHING you experienced over the', 'past 24 hours.', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'NO', 'WORST', 'ITCHING', 'ITCHING', 'IMAGINABLE', 'Date Completed:', 'Time:', 'SUBJECT INITIALS', 'First', 'Middle', 'Last', '2', '0', 'D', 'D', 'M', 'M', 'M', 'Y', 'Y', 'Y', 'Y', 'AM', 'PM', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 86 of 95']"
84,page_85,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 85 of 92', 'CR845-CLIN3102', '14.3', 'Appendix 3: Skindex-10 Scale', 'This is a representation of the content of the instrument to be used. Please refer to the', 'Study Reference Manual for the instrument to be administered to patients and', 'instructions.', 'INSTRUCTIONS: During the past WEEK, how often have you been bothered by:', '0', '1', '2', '3', '4', '5', '6', '(Never', '(Always', 'bothered)', 'bothered)', '1. Your itching', '2. The persistence/reoccurrence', 'of your itching', '3. The appearance of your skin', 'from scratching', '4. Frustration about your itching', '5. Being annoyed about your', 'itching', '6. Feeling depressed about your', 'itching', '7. Feeling embarrassed about', 'your itching', '8. The effects of your itching on', 'your interactions with others', '(for example: interactions with', 'family, friends, close', 'relationships, etc.)', '9. The effects of your itching on', 'your desire to be with people', '10. The effect of your itching', 'making it hard to work or do', 'what you enjoy', 'Date Completed:', 'Time:', 'SUBJECT INITIALS', 'First', 'Middle', 'Last', '2', '0', 'D', 'D', 'M', 'M', 'M', 'Y', 'Y', 'Y', 'Y', 'AM', 'PM', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 87 of 95']"
85,page_86,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 86 of 92', 'CR845-CLIN3102', '14.4', 'Appendix 4: 5-D Itch Scale', 'This is a representation of the content of the instrument to be used. Please refer to the', 'Study Reference Manual for the instrument to be administered to patients and', 'instructions.', '1.', 'DURATION:', 'During the last 2 weeks, how many hours a day have you been itching?', 'Less than', '6 hrs/day', '6-12 hrs/day', '12-18 hrs/day', '18-23 hrs/day', 'All day', '2.', 'DEGREE:', 'Please rate the intensity of your itching over the past 2 weeks', 'Not', 'present', 'Mild', 'Moderate', 'Severe', 'Unbearable', '3.', 'DIRECTION:', 'Over the past 2 weeks has your itching gotten better or worse', 'compared to the previous month?', 'Completely', 'Much better, but', 'Little bit better,', 'Getting', 'resolved', 'still present', 'but still present', 'Unchanged', 'Worse', '4.', 'DISABILITY:', 'Rate the impact of your itching on the following activities over the last 2', 'weeks', 'Delays falling', 'Delays falling', 'Frequently', 'asleep and', 'asleep and', 'Never', 'Occasionally', 'delays', 'occasionally', 'frequently', 'affects', 'delays falling', 'falling', 'wakes me up', 'wakes me up', 'sleep', 'asleep', 'asleep', 'at night', 'at night', 'Sleep', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Always', 'affects', 'affects', 'affects', 'affects', 'affects', 'this', 'this', 'this', 'this', 'this', 'N/A', 'activity', 'activity', 'activity', 'activity', 'activity', 'Leisure/Social', 'Housework/', 'Errands', 'Work/School', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 88 of 95']"
86,page_87,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 87 of 92', 'CR845-CLIN3102', '5.', 'DISTRIBUTION:', 'Mark whether itching has been present in the following parts of your', 'body over the last 2 weeks. If a body part is not listed, choose the one', 'that is closest anatomically.', 'Head/Scalp', 'Soles', 'Face', 'Palms', 'Chest', 'Tops of Hands/Fingers', 'Abdomen', 'Forearms', 'Back', 'Upper Arms', 'Buttocks', 'Points of Contact w/', 'Clothing (e.g waistband,', 'Thighs', 'undergarment)', 'Lower legs', 'Groin', 'Tops of Feet/Toes', 'Date Completed:', 'Time:', 'SUBJECT INITIALS', 'First', 'Middle', 'Last', '2', '0', ':', 'D', 'D', 'M', 'M', 'M', 'Y', 'Y', 'Y', 'Y', 'AM', 'PM', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 89 of 95']"
87,page_88,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 88 of 92', 'CR845-CLIN3102', '14.5', 'Appendix 5: Patient Global Impression of Change', 'This is a representation of the content of the instrument to be used. Please refer to the', 'Study Reference Manual for the instrument to be administered to patients and', 'instructions.', 'Since the start of the study, my itch is:', '1.', 'Very much improved', '2.', 'Much improved', '3.', 'Minimally improved', '4.', 'Not changed', '5.', 'Minimally worse', '6.', 'Much worse', '7.', 'Very much worse', 'Date Completed:', 'Time:', 'SUBJECT INITIALS', 'First', 'Middle', 'Last', '2', '0', 'D', 'D', 'M', 'M', 'M', 'Y', 'Y', 'Y', 'Y', 'AM', 'PM', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 90 of 95']"
88,page_89,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 89 of 92', 'CR845-CLIN3102', '14.6', 'Appendix 6: Short Opiate Withdrawal Scale', 'This is a representation of the content of the instrument to be used. Please refer to the', 'Study Reference Manual for the instrument to be administered to patients and', 'instructions.', 'INSTRUCTIONS: Please mark the appropriate box if you have suffered from any of the', 'following conditions in the LAST 24 HOURS:', '0', '1', '2', '3', 'NONE', 'MILD', 'MODERATE', 'SEVERE', '1. Feeling sick', '2. Stomach cramps', '3. Muscle spasms/twitching', '4. Feelings of coldness', '5. Heart pounding', '6. Muscular tension', '7. Aches and pains', '8. Yawning', '9. Runny eyes', '10. Insomnia/problems sleeping', 'Date Completed:', 'Time:', 'SUBJECT INITIALS', 'First', 'Middle', 'Last', '.', '2', '0', 'D', 'D', 'M', 'M', 'M', 'Y', 'Y', 'Y', 'Y', 'AM', 'PM', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 91 of 95']"
89,page_90,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 90 of 92', 'CR845-CLIN3102', '14.7', 'Appendix 7: Objective Opiate Withdrawal Scale', 'This is a representation of the content of the instrument to be used. Please refer to the', 'Study Reference Manual for the instrument to be administered to patients and', 'instructions.', 'INSTRUCTIONS: Observe the patient during a 5 MINUTE period, then indicate a score', 'for each of the items listed below:', '0', '1', '1. Yawning', 'no yawns', '1 yawn', '2. Rhinorrhea', '< 3 sniffs', '3 sniffs', '3. Piloerection (observe arm)', 'absent', 'present', '4. Perspiration', 'absent', 'present', '5. Lacrimation', 'absent', 'present', '6. Tremor (hands)', 'absent', 'present', '7. Mydriasis', 'absent', '3 mm', '8. Hot and Cold flushes', 'absent', 'shivering / huddling for warmth', '9. Restlessness', 'absent', 'frequent shifts of position', '10. Vomiting', 'absent', 'present', '11. Muscle twitches', 'absent', 'present', '12. Abdominal cramps', 'absent', 'Holding stomach', '13. Anxiety', 'absent', 'mild severe', 'Date Completed:', 'Time:', '2', '0', 'D', 'D', 'M', 'M', 'M', 'Y', 'Y', 'Y', 'Y', 'AM', 'PM', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 92 of 95']"
90,page_91,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 91 of 92', 'CR845-CLIN3102', '15.0', 'Statistical Appendix', 'This appendix provides further details related to the treatment of missing data for the', 'primary and sensitivity analyses of the primary endpoint.', 'For multiple imputations and other instances where random seeds are required, the values', 'used (in order) are:', '8392857', '2985729', '1843255', '9086284', '5547484', '8017456', '9597295', '2252256', '4821871', '9852467', '5126715', '3232132', '9841654', '3645284', '1587345', 'Note that not all seeds may be required in programming the multiple imputations. If', 'additional seeds are needed, they will be chosen by adding 1 to each of the values above,', 'again using them in order.', 'The number of imputations for the multiple imputations will be 20.', 'For the primary analysis, a multi-stage process will be applied:', 'Stage 1: Subjects will have their 11-point NRS scores imputed. First, using all visits,', 'intermittent missing data will be imputed using the Markov Chain Monte Carlo (MCMC)', 'method implemented with the SAS MI procedure; data imputed following subject', 'discontinuation via this process will be censored out of the resulting dataset so that only', 'intermittent missing data is imputed via this method. Second, monotone missing data', 'will be imputed following subject discontinuation using SAS proc MI. For each stage,', 'MI will be performed within treatment group with covariates for baseline NRS score, use', 'of prior anti-itch medication, and presence of select medical conditions. Should', 'convergence issues occur due to small cell size for the one or both of the categorical', 'covariates at either stage, the appropriate covariate(s) will be removed from the model.', 'Stage 2: Using the resulting complete datasets, the change from baseline with respect to', 'the 11-point NRS will be calculated; patients will be categorized as responder if they', 'have a 3-point (or greater) improvement over baseline. Week 12 values will serve as the', 'primary timepoint. The 20 MI runs will be analyzed independently using a logistic', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 93 of 95']"
91,page_92,"['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 92 of 92', 'CR845-CLIN3102', 'model and the results combined using SAS proc MIANALYZE. Logistic model', 'covariates will include treatment, baseline NRS score, use of prior anti-itch medication,', 'and presence of select medical conditions. As with the MI, should convergence issues', 'occur due to small cell sizes, the appropriate categorical covariate(s) will be dropped as', 'necessary.', 'Should a sample size increase occur, the above process will be implemented completely', 'independently among subjects contributing the interim results and those following the', 'interim analysis.', 'For the tipping point analysis, a shift parameter will be applied to only subjects in the', 'active group, running from 0 to 5 points in 0.25-point increments or until the conclusions', 'of the analysis ""tip"" and the results are no longer significant. This analysis will not be', 'performed should the initial primary results fail to achieve significance.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 94 of 95']"
